Page last updated: 2024-09-04

cinacalcet and Hyperparathyroidism, Secondary

cinacalcet has been researched along with Hyperparathyroidism, Secondary in 509 studies

Research

Studies (509)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	183 (35.95)	29.6817
2010's	280 (55.01)	24.3611
2020's	46 (9.04)	2.80

Authors

Authors	Studies
Areepium, N; Auamnoy, T; Eiam-Ong, S; Katavetin, P; Ngamkam, J; Praditpornsilpa, K; Susantitaphong, P; Takkavatakarn, K; Tiranathanagul, K; Vadcharavivad, S	1
Chon, Y; Drayer, D; Goodman, WG; Lai, J; Martin, KJ; Moore, C; Nemeth, EF; Ward, DT; Xu, J	1
Anayama, M; Kurihara, S; Makino, Y; Nagasawa, M; Nakamura, H; Tamura, K; Tokumoto, M	1
Ahmad, A; Alkhalili, E; Alvarado, L; Dwivedi, A; Hechanova, A; Lerma, R; Nwosu, A; Payan-Schober, F; Sharma, N	1
Idasiak-Piechocka, I; Lacka, K; Miedziaszczyk, M; Wiśniewski, OW	1
Fujii, N; Fukagawa, M; Hamano, T; Komaba, H; Masakane, I; Moriwaki, K; Nitta, K; Wada, A	1
Ahn, JB; Mathur, A; McAdams-DeMarco, M; Segev, DL; Sutton, W; Zeiger, MA	1
Chen, J; Chen, W; Fan, C; Huang, B; Tao, Y; Wang, H; Wang, M; Wen, D; Zhang, M; Zhang, W	1
Blanchard, C; Caillard, C; Figueres, L; Frey, S; Goronflot, T; Gourraud, PA; Hourmant, M; Kerleau, C; Mirallié, É; Wargny, M	1
Chertow, GM; Lenihan, CR; Liu, S; Montez-Rath, ME; Wang, AX	1
Akizawa, T; Asada, S; Endo, Y; Fukagawa, M; Kurita, N; Tokumoto, M; Tokunaga, S	1
Craus, S; Mifsud, EL; Mifsud, S; Vella, S	1
Agafonova, E; Jankovic, L; Morosetti, M; Pryshlyak, I; Zappalà, L	1
Bacchetta, J; Bernardor, J; De Mul, A; Schmitt, CP	1
Cheung, SC; Lang, BH; Lo, WK; Tang, TK; Wang, AY; Yau, YY	1
Evenepoel, P; Jørgensen, HS	1
Fung, MM; Lang, BH; Lui, DT; Tam, DS	1
Chen, H; Disharoon, M; Fazendin, J; Gillis, A; Lindeman, B; McLeod, MC; McMullin, JL; Ong, S; Price, G; Stidham, G; Wang, R	1
Bakhle, D; Bhonde, M; Chaudhari, VD; Gandhe, A; Ghodke, R; Goel, R; Gote, G; Gundu, J; Kamboj, RK; Khan, T; Kulkarni, S; Loriya, R; Mahajan, N; Mehta, M; Modak, V; Modi, D; Narasimham, L; Nigade, P; Pachpute, V; Palle, VP; Patil, V; Pawar, C; Pawar, S; Phadtare, R; Sabde, S; Sadasivam, G; Sarde, A; Sayyed, M; Shah, C; Sharma, S; Shukla, MR; Tryambake, M; Walke, N	1
Honda, H; Kato, T; Kawata, T; Kitayama, T; Koiwa, F; Mizobuchi, M; Ogata, H; Saito, T; Sakai, M; Suzuki, T	1
Beninato, T; Egan, CE; Fahey, TJ; Finnerty, BM; Greenberg, JA; Lee, J; Lee-Saxton, YJ; Qazi, M; Zarnegar, R	1
Ding, W; Li, X; Zhang, H	1
Ginsberg, C; Ix, JH	1
Barreto, FC; Bucharles, SGE; Riella, MC	1
Fuertinger, DH; Kotanko, P; Schappacher-Tilp, G	1
Anagnostis, P; Tournis, S; Vamvakidis, K	1
Fu, P; Ma, L; Peng, H; Xu, J; Yang, Y	1
Geer, J; Joseph, C; Juarez-Calderon, M; Shah, S; Srivaths, PR; Swartz, SJ	1
Ariceta, G; Bacchetta, J; Bakkaloglu, SA; Groothoff, J; Haffner, D; Schmitt, CP; Shroff, R; Vervloet, M; Wan, M	1
Centeno, PP; Chavez-Abiega, S; Elajnaf, T; Goedhart, J; Kallay, E; Mos, I; Schlattl, W; Ward, DT	1
Li, H; Lu, X; Song, J; Wang, S; Yu, L; Zu, Y	1
Erhard, C; Floege, J; Fouqueray, B; Louie, KS; Stenvinkel, P; Wheeler, DC	1
Honda, H; Koiwa, F; Mizobuchi, M; Ogata, H	1
Bacchetta, J; Bloss, L; Mo, M; Ng, E; Schaefer, F; Warady, BA	1
Bacchetta, J; Bernardor, J; Büscher, A; Dello Strologo, L; Genc, G; John, U; Krupka, K; Oh, J; Schmitt, CP; Sellier-Leclerc, AL; Tönshoff, B; Weitz, M; Zirngibl, M	1
Bestard, O; Codina, S; Coloma, A; Cruzado, JM; Francos, J; García-Barrasa, A; Manonelles, A; Melilli, E; Montero, N; Moreno, P; Torregrosa, JV	1
Johnson, DW; Mavridis, D; Palmer, SC; Ruospo, M; Strippoli, GFM; Tonelli, M	1
Endo, Y; Fukagawa, M; Hamano, N; Kawata, T	1
Hiramitsu, T; Ichimori, T; Okada, M; Tominaga, Y; Tomosugi, T; Tsuzuki, T	1
Wetmore, JB	1
Al-Kofahi, M; Basu, C; Brundage, R; Carlin, BP; Ma, X; Mo, M; Xia, HA	1
Cavalier, E; Evenepoel, P; Jørgensen, HS	1
Hur, C; Kuo, JH; Lee, JA; McManus, C; Oh, A	1
Fomenko, MS; Pavlov, AA; Sheng, Z; Shilenko, PA; Shneider, YA; Sun, Y; Tian, B; Tsoi, MD; Wan, P; Xu, T; Yao, L	1
Hong, D; Liu, L; Lu, X; Ma, K; Wu, B	1
Fukagawa, M; Hirata, K; Imafuku, T; Kadowaki, D; Kato, H; Komaba, H; Maeda, H; Maruyama, T; Matsushita, K; Miyamura, S; Nakano, T; Otagiri, M; Tanaka, M; Tanaka, S; Tokunaga, K; Watanabe, H	1
Ahn, JB; Mathur, A; McAdams-DeMarco, M; Prescott, JD; Segev, DL; Sutton, W; Zeiger, MA	1
Alderson, H; Bubtana, A; Chinnadurai, R; Chrysochou, C; Eddington, H; Erekosima, I; Green, D; Hegarty, J; Hutchison, A; Ibrahim, ST; Kalra, PA	1
Caillard, C; Figueres, L; Frey, S; Goronflot, T; Gourraud, PA; Hourmant, M; Kerleau, C; Mirallié, É	1
Fligor, SC; Hamaguchi, R; James, BC; Li, C; William, J	1
Bradbury, BD; Dluzniewski, PJ; Gilbertson, DT; Guo, H; Lin, TC; Liu, J; Nieman, K; Peng, Y; Sprafka, JM; Wetmore, JB	1
Cai, L; Fang, W; He, X; Li, X; Wang, X; Wu, H; Xu, X; Zhang, Z	1
Ayav, C; Brunaud, L; Filipozzi, P; Frimat, L; Kessler, M; Laurain, E; Ngueyon Sime, W	1
Adragão, T; Barata, JD; Branco, P; Conde, SQ; Gaspar, A; Sousa, H	1
Carney, G; Choi, JDW; Chong, GC; Lee, TT	1
de Borst, MH; Dulfer, RR; Engelsman, AF; Kruijff, S; van der Plas, WY; van Ginhoven, TM; Vogt, L	1
Hernández, AM; Llorente, S; Parrilla, P; Ríos, A; Rodríguez, JM; Ruiz, J	1
Friedl, C; Kramar, R; Mann, JFE; Pilz, S; Reibnegger, G; Rosenkranz, AR; Zitt, E	1
Dulfer, RR; Franssen, GJH; Hesselink, DA; Hoorn, EJ; van Eijck, CHJ; van Ginhoven, TM	1
Guettier, JM; Hai, MTT; Rosebraugh, CJ	1
Block, GA; Chertow, GM	1
Sin, HY	1
Brown, AJ; Coyne, DW; Gupta, D; Miller, B; Ritter, C; Slatopolsky, E; Zheng, S	1
Bossola, M; Vulpio, C	2
Bradbury, BD; Brookhart, MA; Dluzniewski, PJ; Kshirsagar, A; Reams, D; Walsh, L	1
Fuse, M; Kada, S; Takada, D; Tsukamoto, T; Yanagita, M	1
Dryl-Rydzyńska, T; Marcinkowski, W; Małyszko, J; Małyszko, JS; Prystacki, T; Zawierucha, J	1
Chen, X; Liu, H; Wang, C; Yuan, F; Zhou, A	1
Fyssa, L; Goumenos, DS; Ntrinias, T; Papachristou, E; Papasotiriou, M; Savvidaki, E; Zavvos, V	1
Alon, US; Jafri, S; Manimtim, WM; Sebestyen VanSickle, J; Srivastava, T; Truog, WE	1
Bover, J; Cohen-Solal, M; Ureña Torres, PA	1
Cozzolino, M	1
Cozzolino, M; Messa, P	1
Ohno, Y; Oshima, J; Otsuka, K	1
Cannavò, R; Cestone, G; Cirillo, L; Cutruzzulà, R; Dattolo, PC; Errichiello, C; Gallo, P; Gregori, M; Mehmetaj, A; Sorrentino, A	1
Barany, P; Birnie, K; Carrero, JJ; Caskey, FJ; Evans, M; Gasparini, A; MacNeill, S; May, MT; Methven, S	1
Adena, M; Akehurst, R; Belozeroff, V; Briggs, A; Dehmel, B; Iannazzo, S; Parfrey, P; Stollenwerk, B	1
Rothe, HM	1
Chang, TJ; Hsu, YH; Hung, CF; Liao, MT; Lin, YF; Lu, CL; Lu, KC; Shyu, JF; Wang, YH; Wu, CC; Zheng, CM; Zheng, JQ	1
Gu, W; Ji, X; Liu, H; Mu, Y; Wang, C; Wang, G	1
Bonewald, LF; Inaba, M; Ito, A; Nitta, K; Tanizawa, T; Tominaga, Y; Tsuchiya, K; Yajima, A	1
Chertow, GM; Drueke, TB; Floege, J; Iles, J; Parfrey, P; Tsirtsonis, K	1
Rroji, M; Spasovski, G	1
Ago, T; Arakawa, S; Kimura, S; Kitazono, T; Ohya, Y; Osaki, M; Sakai, S; Yasuda, C	1
Belozeroff, V; Bennett, H; Bensink, ME; Block, GA; Chertow, GM; Cooper, K; Goring, S; Levy, AR; Lozano-Ortega, G; Trotman, ML; Waser, N	1
Bednarski, D; Grzegorzewska, AE; Jagodziński, PP; Mostowska, A; Świderska, M	1
Hewitson, TD; Holt, SG; Ruderman, I; Smith, ER; Toussaint, ND	1
Bellasi, A; Cancarini, G; Cozzolino, M; Esposito, C; Genderini, A; Guastoni, CM; Locatelli, F; Malberti, F; Messa, P; Ondei, P; Pontoriero, G; Teatini, U; Vezzoli, G	1
Evenepoel, P; Shroff, R	1
Adamczak, M; Kuczera, P; Machnik, G; Okopien, B; Wiecek, A	2
Friedl, C; Zitt, E	1
Baker, D; Callahan, RE; Czako, PF; Lloyd, LR; Nagar, S; Sevak, S	1
Chertow, GM; Decker, BS; Edenberg, HJ; Foroud, TM; Long, J; Moe, SM; Schwantes-An, TL; Vatta, M; Wetherill, L; Xuei, X	1
Au, E; Elder, GJ; Gock, H; Gray, NA; Hawley, CM; Holt, SG; Kirkland, GS; Krishnasamy, R; Mainra, R; Maslen, S; Nelson, CL; Oliver, V; Rajaram, Y; Ruderman, I; Talaulikar, GS; Toussaint, ND	1
Eidman, KE; Wetmore, JB	1
Akizawa, T; Fukagawa, M; Shimazaki, R	2
Akizawa, T; Fukagawa, M; Shimazaki, R; Shiramoto, M	2
Abitbol, CL; Arenas Morales, AJ; Chandar, J; DeFreitas, MJ; Freundlich, M; Katsoufis, CP; Seeherunvong, W; Zilleruelo, G	1
Parfrey, PS	1
Delbridge, LW; Dulfer, RR; Engelsman, AF; Kruijff, S; van der Plas, WY; van Ginhoven, TM; Vriens, MR	1
Delbridge, LW; Engelsman, AF; Kruijff, S; Mather, A; Pollock, C; Sidhu, SB; Sywak, MS; Umakanthan, M; van der Plas, WY; Waugh, D	1
Ariceta, G; Dehmel, B; Hidalgo, G; Iles, JN; Jiang, X; Laskin, B; Schaefer, F; Shahinfar, S; Vande Walle, J; Warady, BA	1
Srinivas, NR	1
Nigwekar, SU; Seethapathy, H	1
Chertow, GM; Franchetti, Y; Liu, S; Long, J; Mahnken, JD; Nolin, TD; Prokopienko, AJ; Stedman, MR; Stubbs, JR; West, RE	1
Chertow, GM; Decker, BS; Edenberg, HJ; Foroud, TM; Liu, S; Moe, SM; Schwantes-An, TH; Stedman, M; Vatta, M; Wetherill, L	1
Arias-Guillén, M; Broseta, JJ; Filella, X; Fontseré, N; Maduell, F; Montagud-Marrahi, E; Ojeda, R; Rodas, L; Rubio, MV; Torregrosa, V; Vera, M; Xipell, M	1
Chou, H; Inaba, M; Ishimura, E; Nakatani, S; Okuno, S; Shoji, S; Yamakawa, T	1
Chen, P; Gisleskog, PO; Melhem, M; Narayanan, A; Sohn, W	1
Mazzaferro, S; Pasquali, M	1
Alexander, RT; Beggs, MR; Chen, XZ; Dimke, H; Flockerzi, V; Lee, JJ; Liu, X; O'Neill, D; Weissgerber, P	1
Dumrongpisutikul, N; Eiam-Ong, S; Jakchairoongruang, K; Praditpornsilpa, K; Singhan, W; Susantitaphong, P; Susomboon, T; Vadcharavivad, S	1
Chung, WY; Jeong, JJ; Kang, SW; Kim, BS; Kim, K; Kim, WW; Lee, CR; Lee, J; Nam, KH; Rhee, Y	1
Endo, Y; Kawata, T; Tokunaga, S	1
Almadén, Y; Arenas, MD; de la Fuente, V; Delgado, P; Gil, MT; Gutiérrez, P; Ribero, J; Rodríguez, M	1
Chang, YS; Choi, BS; Choi, SR; Chung, BH; Chung, S; Hong, YA; Kim, MY; Kim, YS; Lim, JH; Park, CW; Yang, CW	1
Biechy-Baldan, Mdel M; Borrego-Utiel, FJ; Pérez-del Barrio, Mdel P; Segura-Torres, P	1
Bossola, M; Di Stasio, E; Fadda, G; Silvestri, P; Tazza, L; Vulpio, C	1
Fukagawa, M; Kakuta, T; Komaba, H	1
Abbachi, F; Abouchacra, S; Bernsen, R; Chaaban, A; Gebran, N; Haq, N; Hassan, M; Khan, I	1
Kilpatrick, RD; Liu, J; Newsome, BB; Nieman, K; Solid, CA; St Peter, WL; Zaun, D	1
Inoshita, N; Marui, Y; Nakamura, M; Ohashi, K; Sumida, K; Takaichi, K; Tanaka, K; Tomikawa, S; Ubara, Y	2
Chen, TC; Chiu, TT; Kuo, CC; Lee, CT; Lee, WC; Lee, YT; Ng, HY; Wu, CS	1
Cardinal, H; Lafrance, JP; Le Lorier, J; Leblanc, M; Madore, F; Pichette, V; Roy, L	1
Matuszkiewicz-Rowińska, J; Staszków, M; Wojtaszek, E; Żebrowski, P	1
Kitazono, T; Tsuruya, K; Yamada, S	1
Flechner, SM; Seager, CM; Srinivas, TR	1
Ketteler, M; Khan, SS; Marshall, TS; Schumock, GT; Sharma, A	1
Belozeroff, V; Campbell, JD; Chiroli, S; Lee, A; Tseng, S	1
Adamczak, M; Kuczera, P; Więcek, A	4
Burnier, M; Forni Ogna, V; Pruijm, M; Tousset, E; Wuerzner, G; Zweiacker, C	1
du Buf-Vereijken, PW; Manamley, N; Potter van Loon, BJ; Reichert, LJ; Smak Gregoor, PJ; Vervloet, MG	1
Charytan, C; Yousaf, F	1
Albero-Molina, MD; Álvarez-Avellán, L; del Pozo-Fernández, C; López-Menchero-Martínez, R; Sánchez-Rodríguez, L	1
Moe, SM; Thadhani, R	1
Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; London, GM; Mahaffey, KW; Modafferi, DM; Moe, SM; Parfrey, PS; Trotman, ML; Wheeler, DC	1
Bellasi, A; Floege, J; Goodman, W; Pétavy, F; Raggi, P; Reiner, M	1
Johns, B; Khan, SS; Marshall, TS; Sharma, A	1
Barros, X; Torregrosa, JV	1
Flanagan, D; Mancini, M	1
Bravo, J; Crespo, J; Díaz, JM; García, MR; Gentil, MÁ; Gómez Alamillo, C; Gómez, G; Gutiérrez Dalmau, A; Jiménez, VL; Jimeno, L; Morales, E; Rodríguez Benot, A; Romero, R; Sáez, MJ; Torregrosa, JV	1
Grzegorzewska, AE; Ostromecki, G	1
Biggar, P; Graf, H; Ketteler, M; Klauser-Braun, R; Kovarik, J; Müller, HW; Seidinger, S; Veres, A	1
Bravo, J; Crespo, J; Díaz, JM; Gentil, MA; Gómez, G; Gómez-Alamillo, C; Gutiérrez-Dalmau, Á; Jimeno, L; López-Jiménez, V; Morales, E; Pérez-Sáez, MJ; Rodríguez-Benot, A; Rodríguez-García, M; Romero, R; Torregrosa, JV	1
Fukagawa, M; Kakuta, T; Kanai, G; Komaba, H; Sawada, K; Suzuki, H; Takahashi, H; Takahashi, Y; Tatsumi, R	1
Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Sharma, A	1
Fukagawa, M; Kakuta, T; Kanai, G; Komaba, H; Miyakogawa, T; Sawada, K; Tatsumi, R	1
Cheng, PM; Chow, KM; Kwan, BC; Leung, CB; Li, PK; Pang, WF; Szeto, CC	1
Ayav, C; Briançon, S; Brunaud, L; Erpelding, ML; Frimat, L; Kessler, M; Laurain, E	1
Behets, GJ; D'Haese, PC; De Broe, ME; Goodman, WG; Spasovski, G; Spiegel, DM; Sterling, LR	1
Abdalla, S; Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Trotman, ML; Wheeler, DC	1
Chen, H; Schneider, DF; Sippel, RS; Somnay, YR; Weinlander, E	1
Ballinger, AE; Craig, JC; Nistor, I; Palmer, SC; Strippoli, GF	1
Hénaut, L; Larsson, TE; Massy, ZA; Vervloet, MG	1
Abdalla, S; Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Wheeler, DC	1
Andreucci, VE; Bieber, BA; Frimat, L; Fukagawa, M; Jacobson, SH; Karaboyas, A; Li, Y; Mendelssohn, DC; Pisoni, RL; Port, FK; Robinson, BM; Tentori, F; Wang, M	1
Abukhatwah, MW; Alharthi, AA; Kamal, NM; Sherief, LM	1
Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Wheeler, DC	1
Eriguchi, R; Fujimi, S; Kitazono, T; Ooboshi, H; Suehiro, T; Taniguchi, M; Tokumoto, M; Toyonaga, J; Tsuruya, K; Yamada, S	1
Buerkert, J; Cooper, K; Da Roza, G; Goodman, W; Gurevich, K; Reiner, M; Sprague, SM; Wetmore, JB	1
Bradbury, BD; Collins, AJ; Do, T; Liu, J; Lowe, KA; Nieman, KM; St Peter, WL; Yusuf, AA	1
Chertow, GM; Floege, A; Floege, J; Kubo, Y; Parfrey, PS	1
Biggar, PH; Ketteler, M	1
Buerkert, J; Cooper, K; Da Roza, G; Goodman, W; Gurevich, K; Reiner, M; Sprague, S; Wetmore, JB	1
Covic, A; Cozzolino, M; Goldsmith, D; Nistor, I; Vervloet, M	1
Lorenzoni, V; Trieste, L; Turchetti, G	1
Cho, YS; Hong, YA; Hwang, SY; Jung, MY; Kim, SW; Ko, GJ; Kwon, YJ; Lee, EA; Pyo, HJ; Suh, S	1
Ballarín, J; Bover, J; Cozzolino, M; daSilva, I; del Carpio, J; Lescano, P; Ruiz-García, C; Ureña, P	1
Bradbury, BD; Brunelli, SM; Cooper, K; Dluzniewski, PJ; Do, TP; Sibbel, S	1
Erb, H; Hemetsberger, M; Oberbauer, R; Pronai, W	1
Acosta Martínez, Y; Borrego Utiel, FJ; Bravo Soto, JA; García Álvarez, T; González Carmelo, I; López Jiménez, V; Mazuecos Blanca, MA; Merino Pérez, MJ	1
Duarte-Gallego, V; Esteve Simo, V; Fulquet Nicolas, M; Macias-Toro, J; Martínez Calvo, G; Moreno-Guzmán, F; Pou Potau, M; Ramírez-de Arellano Serna, M; Saurina Sole, A	1
Aronova, A; Ayav, C; Brunaud, L; Filipozzi, P; Frimat, L; Kessler, M; Ngueyon Sime, W; Nomine-Criqui, C; Zarnegar, R	1
Bradbury, BD; Brookhart, MA; Dluzniewski, PJ; Do, TP; Kshirsagar, AV; Reams, BD; Yue, SV	1
Aamer, MA; Bashir, SO; Morsy, MD; Omer, HA; Somialy, R	1
Block, GA; Chertow, GM; Correa-Rotter, R; Drüeke, TB; Floege, J; Herzog, CA; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Wheeler, DC	1
Bestard, O; Cruzado, JM; Francos, J; García-Barrasa, A; Gómez-Vaquero, C; Grinyó, JM; Mast, R; Moreno, P; Polo, C; Revuelta, I; Taco, O; Torras, J; Torregrosa, JV	1
de Francisco, AL; Drueke, TB; Floege, J; Froissart, M; Gillespie, IA; Gioni, I; Kronenberg, F; Marcelli, D; Wheeler, DC	1
Belozeroff, V; Briggs, AH; Chertow, GM; Dehmel, B; Graham, CN; Parfrey, PS	1
Micozkadioglu, H; Nursal, GN; Ozelsancak, R; Torun, D; Yigit, F; Yildiz, I	1
Kadokura, Y; Kakuta, T; Nakamura, M; Tahara, H; Tominaga, Y; Yasunaga, C	1
Bravo, J; Castilla, YA; Esteban, MA; Esteban, RJ; Fernández-Castillo, R; García-Valverde, M; Nozal-Fernández, G; Orellana, JM	1
Chen, N; Ding, X; Hou, F; Jiang, G; Li, X; Liu, H; Mei, C; Qian, J; Wang, L; Wang, M; Wang, N; Yu, X; Zuo, L	1
Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Kurita, N; Kurokawa, K; Onishi, Y; Yokoyama, K	1
Belozeroff, V; Briggs, AH; Chertow, GM; Dehmel, B; Khan, N; Kubo, Y; Parfrey, PS; Tseng, S	1
Akizawa, T; Alan Brookhart, M; Ellis, AR; Fukagawa, M; Fukuhara, S; Fukuma, S; Hasegawa, T; Kurita, N; Kurokawa, K; Mizobuchi, M; Onishi, Y; Yamaguchi, T	1
Ballarin, J; Bover, J; DaSilva, I; Diaz-Encarnacion, MM; Fernández, E; Lloret, MJ; Mateu, S; Mercado, C; Ruiz, C; Ureña-Torres, P	1
Chen, L; Duan, W; Lai, L; Wang, K; Yu, S; Yuan, J; Zhang, X	1
Chertow, GM; Kim, SM; Leonard, MB; Long, J; Montez-Rath, ME; Norton, JA	1
Buttar, RS; Coco, M; Melamed, ML	1
de Borst, MH; Engelsman, AF; Kruijff, S; Meijer, K; Özyilmaz, A; Pol, RA; van Dam, GM; van der Horst-Schrivers, AN; van der Plas, WY	1
Han, N; Jeong, S; Joo, KW; Kim, HJ; Kim, IW; Oh, JM; Oh, KH	1
Dryl-Rydzyńska, T; Marcinkowski, W; Małyszko, J; Prystacki, T; Zawierucha, J	1
Alcalde-Rodrigo, M; Galicia-Basart, M; Montoro-Ronsano, JB; Pérez-Ricart, A; Segarra-Medrano, A; Suñé-Negre, JM	1
Darwish, H; Elbanna, E; Maamoun, HA; Soliman, AR; Soliman, MA	1
Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Ito, K; Matsushita, K; Tanaka, M; Yoshida, K	1
Akıncı, A; Dündar, İ; Kıvılcım, M	1
Enoki, Y; Fukagawa, M; Ikegami, K; Imafuku, T; Ishima, Y; Komaba, H; Maruyama, T; Matsushita, K; Miyamura, S; Murata, M; Nishida, K; Otagiri, M; Sakaguchi, Y; Sugimoto, R; Tanaka, M; Watanabe, H	1
Bock, A; Hemetsberger, M; Jäger, C; Klauser-Braun, R; Lhotta, K; Pendl, G; Pronai, W; Rosenkranz, AR	1
Block, GA; Bushinsky, DA; Cheng, S; Chertow, GM; Cunningham, J; Dehmel, B; Drueke, TB; Ketteler, M; Kewalramani, R; Martin, KJ; Moe, SM; Patel, UD; Silver, J; Sun, Y; Wang, H	1
Dralle, H	1
Fukagawa, M; Hamano, N; Komaba, H	1
Fukagawa, M; Komaba, H; Tanaka, M	1
Evenepoel, P	1
Bahner, U; Brandl, M; Nies, C; Schmidt-Gayk, H	1
Cointault, O; Durand, D; Esposito, L; Gandia, P; Gennero, I; Guitard, J; Kamar, N; Lavayssière, L; Rostaing, L; Spataru, L	1
Floege, J; Schlieper, G	1
Aljama, P; Almaden, Y; Cañadillas, S; Martin-Malo, A; Rodriguez, M; Rodriguez, ME; Santamaría, R; Valle, C	1
Baczyński, D; Konieczna, M; Nowak, Z; Saracyn, M; Waińkowicz, Z; Wesolowski, P	1
Sane, DC	1
Kebig, A; Mohr, K	1
Bergua, C; Campistol, JM; Fuster, D; Gutierrez-Dalmau, A; Oppenheimer, F; Torregrosa, JV	1
Giotta, N; Marino, A	2
Asensio, C; Bover, J; Carter, D; Dellanna, F; Gross, P; Jehle, PM; Sánchez González, MC; Sanz, D; Schaefer, RM; Zani, V	1
Akizawa, T; Iwasaki, M; Koshikawa, S; Shigematsu, T; Tsukamoto, Y; Uchida, E	1
Kawata, T; Kobayashi, N; Koyama, C; Miyata, S; Nagano, N; Obi, M; Wada, M; Wakita, S	1
Alvarez-Ude, F; Arenas, MD; Gil, MT; Malek, T; Moledous, A; Núñez, C; Prieto, L; Rebollo, P	1
Agroyannis, B; Agroyannis, I; Gombou, A; Griveas, I; Kyritsis, I; Retsa, K	1
Fernández Giráldez, ED	1
Charytan, C; Corry, DB; Fishbane, S; Goodman, WG; Ling, X; Rappaport, K; Roppolo, M; Shapiro, WB; Turner, S; Vicks, SL	1
Hasegawa, T; Hosoya, T; Nakano, H; Nakayama, M; Okazaki, M; Takeguchi, F; Terawaki, H	1
Kawata, T; Nagano, N; Wada, M	1
Akizawa, T	1
Akizawa, T; Koshikawa, S	1
Kitaoka, M	1
Drüeke, TB	3
Tahara, H	1
Matsuoka, S; Sato, T; Tominaga, Y; Uno, N	1
Fujii, M; Maeda, K; Mizutani, R; Myochin, H; Narita, M; Ohbayashi, T; Tsuruta, Y	1
Akizawa, T; Ito, A; Kurihara, S; Tsukamoto, Y; Yajima, A	1
Fukagawa, M; Komaba, H	3
Hallfeldt, K; Khalil, PN	1
Abboud, HE; Albizem, MB; Block, GA; Charytan, C; Chonchol, M; de Francisco, AL; Jolly, S; Kaplan, M; Kubo, Y; Locatelli, F; Mix, TC; Roger, SD; Sarkar, S	1
Arko, C; Block, GA; Li, Q; Liu, J; Nieman, K; Persky, M; St Peter, WL	1
Kalantar-Zadeh, K; Kovesdy, CP	1
Barsotti, G; Meola, M; Petrucci, I	1
Aladrén Regidor, MJ	1
Belozeroff, V; Goodman, WG; Kalantar-Zadeh, K; Ren, L	1
Filson, J; Nguyen, TV	1
Hamano, T	2
Tominaga, Y	2
Aguilar, A; Andrés, E; Baas, J; Ballarin, J; Bover, J; Canal, C; Farré, N; Lloret, MJ; Marco, H; Olaya, M; Reyes, J; Trinidad, P	1
Bos, WJ; Bouman, K; Braun, J; Brink, H; Carter, D; Frazão, JM; Graf, H; Macário, F; Maduell, F; Messa, P; Pontoriero, G; Reichel, H; Saha, H; Torregrosa, V; von Albertini, B; Wilkie, M; Yaqoob, M; Zani, VJ	1
Ashman, N; Baños, A; Bencova, V; Fouque, D; Jacobson, SH; Leavey, S; Malberti, F; Os, I; Rix, M; Ryba, M; Saha, H; Ureña, P; Vervloet, M; Zani, V; Zitt, E	1
Brandenburg, V; Cozzolino, M	1
Cannata-Andía, JB; Fernández-Martín, JL	1
Himeno, Y; Shigeno, K; Sugimoto, T; Sumi, M; Suzuki, K; Tokumoto, A; Yano, S	1
Harris, R; Padhi, D	1
Brancaccio, D; Ciceri, P; Cozzolino, M; Fallabrino, G; Gallieni, M; Olivi, L; Pasho, S; Volpi, EM	1
Casellas, J; Domenech, B; Fuster, D; Martín, G; Muxí, A; Pons, F; Setoain, X; Solà, O; Torregrosa, JV	1
Yokoyama, K	4
Curzi, MP; Evenepoel, P; González, MT; Husserl, FE; Kopyt, N; Mix, C; Sprague, SM; Sterling, LR; Wong, G	1
Coyne, DW; Gincherman, Y; McKee, C; Moloney, K	1
Burnier, M; Halabi, G; Pruijm, M; Santschi, V; Teta, D; Wuerzner, G	1
Fujimi, S; Hirakata, H; Iida, M; Taniguchi, M; Tokumoto, M; Tsuruya, K; Yamada, S	1
Fukagawa, M; Komaba, H; Nakai, K	1
Hirukawa, T; Kakuta, T; Kanai, G; Saito, A; Sato, A; Sawaya, A; Tanaka, R	1
Imanishi, Y; Inaba, M; Kawata, T; Nishizawa, Y	1
Calvo, BF; Kim, HJ; Meyers, MO; Ollila, DW; Russell, CP; Yeh, JJ	1
Burren, C; Dudley, J; Inward, C; McGraw, M; Platt, C; Saleem, MA; Tizard, J	1
Hirai, T; Nakashima, A; Takasugi, N; Yorioka, N	2
Shaheen, FA; Souqiyyeh, MZ	1
Block, GA; Chertow, GM; Csiky, B; Dehmel, B; Downey, G; Floege, J; Goodman, WG; Lopez, N; Moustafa, M; Naso, A; Nossuli, K; Raggi, P; Torres, PU	1
Cannata-Andía, JB; López-Hernández, F; Rodriguez-García, M; Rodríguez-Puyol, D; Román-García, P; Tuñón-le Poultel, D	1
Chazot, C; Deleaval, P; Hurot, JM; Jean, G; Lorriaux, C; Mayor, B; Terrat, JC; Vanel, T; Vovan, C	1
Chou, H; Ichii, M; Inaba, M; Ishimura, E; Kato, Y; Maekawa, K; Nagasue, K; Nishizawa, Y; Okuno, S; Tsuboniwa, N; Yamakawa, T	1
Bossola, M; Castagneto, M; De Gaetano, A; Di Stasio, E; Giordano, A; Luciani, G; Maresca, G; Vulpio, C; Zagaria, L	1
Imanishi, Y; Inaba, M; Ishimura, E; Kurajoh, M; Nagayama, H; Nishizawa, Y; Okuno, S; Shoji, S; Yamada, S; Yamakawa, T	1
Almirall, J; Castañé, E; Gallardo, X	1
Koiwa, F; Maruta, Y	1
Kakuta, T; Uemura, K	1
Biechy Baldán, MM; Borrego Utiel, FJ; García Cortés, MJ; Pérez Bañasco, V; Sánchez Perales, MC; Segura Torres, P	1
Sulková, SD; Válek, M	1
Andress, DL; Audhya, P; Lee, TA; Marx, SE; Schumock, GT; Walton, SM	1
Smržová, J; Urbánek, T	1
Fujimori, A; Fukagawa, M; Hasegawa, H; Komaba, H; Kurosawa, T; Nakanishi, S; Nishioka, M; Shibuya, K; Shin, J; Tanaka, M	1
Evans, M; Fored, CM	1
Copley, JB; Germain, M; Katznelson, S; Pankewycz, O; Shah, T; Sprague, SM; Stern, L; Turner, SA; Wang, O	1
Ashman, N; Bencova, V; Dehmel, B; Fouque, D; Jacobson, SH; Malberti, F; Os, I; Petavy, F; Rix, M; Ryba, M; Saha, H; Ureña, P; Vervloet, M; Zitt, E	1
Chiroli, S; Eandi, M; Iannazzo, S; Pontoriero, G; Pradelli, L	1
Dehmel, B; Fouque, D; Jacobson, SH; Pétavy, F; Rix, M; Ryba, M; Ureña Torres, P; Zitt, E	1
Fujii, N; Hamano, T; Imai, E; Isaka, Y; Matsui, I; Mikami, S; Rakugi, H; Tomida, K	1
Chazot, C; Jean, G; Terrat, JC; Vanel, T	1
Aalten, J; Hoitsma, AJ; Wetzels, JF	1
Chamberlain, CE; Cho, ME; Duan, Z; Mannon, RB; Reynolds, JC; Ring, MS	1
Bartsch, DK; Fernández, ED; Koch, BM; Kolios, G; Schlosser, K; Schneider, R	1
Chertow, GM; Csiky, B; Dehmel, B; Downey, G; Floege, J; Goodman, WG; Lopez, N; Moustafa, M; Naso, A; Nossuli, K; Raggi, P; Torres, PU	1
Ariza, F; Benavides, B; Bover, J; Miguel, JL; Molina, M; Perez, R; Tornero, F; Torregrosa, JV	1
Floege, J; Groene, HJ; Mühlfeld, A; Seikrit, C	1
Braun, J; Reichel, H	1
Eigner, M; Graf, H; Horn, S; Jäger, C; Kodras, K; Kovarik, J; Pétavy, F; Rosenkranz, AR; Watschinger, B; Zitt, E	1
Torres, PU	2
Bayés, B; Bonet, J; Casals, M; Fernández-Crespo, P; López-Ayerbe, J; Romero, R	1
Pestana Vasconcelos, M; Pinho, LR; Ribeiro Santos, MJ	1
Arkouche, W; Attaf, D; Boumendjel, N; Cardozo, C; Cardozo, J; Fouque, D; Karaaslan, H; Laville, M; Lenz, A; Mpio, I; Pastural-Thaunat, M; Silou, J	1
Alfieri, C; Brezzi, B; Messa, P	1
Inaba, M; Ito, A; Nitta, K; Otsubo, S; Satoh, S; Tominaga, Y; Yajima, A	1
Okimoto, N; Oshiro, Y; Tanaka, H	1
Bravo Soto, J; Esteban de la Rosa, RJ; Fernández Castillo, R; Fernández Gallegos, R; Oliva, N; Vaquero, E	1
Goto, N; Hiramitsu, T; Izumi, K; Nanmoku, K; Nobata, H; Okada, M; Tominaga, Y; Tsujita, M; Uchida, K; Watarai, T; Yamamoto, T	1
Fukagawa, M; Kakuta, T; Koizumi, M; Komaba, H; Tanaka, H	1
Bonomini, M; Brancaccio, D; Cancarini, G; Cannella, G; Caruso, MR; Cascone, C; Costanzo, AM; Cozzolino, M; di Luzio Paparatti, U; Mazzaferro, S; Messa, P	1
Calò, LA; D'Angelo, A; Frigo, AC; Fusaro, M; Gallieni, M; Miozzo, D; Naso, A	1
Attaf, D; Boulanger, H; Flamant, M; Fouqueray, B; Glotz, D; Haymann, JP; Mansouri, R; Mercadal, L; Metivier, F	1
Barsotti, G; Colombini, E; Meola, M; Petrucci, I	1
Fujimori, A; Fukagawa, M; Koizumi, M; Komaba, H; Nakanishi, S	1
Akizawa, T; Fukagawa, M; Fukuhara, S; Hasegawa, T; Kido, R; Kurokawa, K; Onishi, Y; Yamaguchi, T	1
Plosker, GL	1
Arletti, S; Carboni, C; Ferrari, F; Graziani, R; Graziosi, C; Lucchi, L; Malaguti, V; Stipo, L	1
Hatamura, I; Kusano, E; Mato, M; Nakazawa, E; Ogura, M; Onishi, A; Saji, F; Shiizaki, K; Watanabe, Y	1
Khalpey, Z; Tullius, SG	1
Brzosko, S; Hryszko, T; Koc-Zorawska, E; Mysliwiec, M; Rydzewska-Rosolowska, A	1
Baños, A; Dehmel, B; Frazão, JM; Geiger, H; Hagen, EC; Kerr, PG; Mellotte, GJ; Messa, P; Quarles, LD; Urena, P	1
Amdahl, M; Audhya, P; Cozzolino, M; Dumas, E; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Marx, S; Sharma, A	1
Ichii, M; Inaba, M; Ishimura, E; Nishizawa, Y; Okuno, S; Shoji, S; Tsuboniwa, N; Yamakawa, K; Yamakawa, T	1
Martínez, AI; Milán, JA; Salgueira, M	1
Borrajo Prol, M; Camba Caride, M; Conde Rivera, O; Iglesias Lamas, E; López Alarcóon, W; Novoa Fernández, E; Santos Nores, J	1
Chazot, C; Jean, G	1
Belozeroff, V; Diakun, D; Fulcher, N; Goodman, W; Khan, I; Lee, A; Song, X	1
Kinugasa, E; Koiwa, F; Kumata-Maeta, C; Mizobuchi, M; Ogata, H; Shishido, K; Yamamoto, M; Yoshida, N	1
Cornago, I; Gallardo, I; García-Ledesma, P; Hernando, A; Martinez, I; Montenegro, J; Muñoz, RI; Romero, MA	1
Colloton, M; Davis, J; Henley, CM; Martin, D; Miller, G; Shatzen, E	1
Inoue, T; Kikuta, T; Sato, T; Suzuki, H; Tsuda, M; Uchida, K; Watanabe, Y	1
Baxter, P; Ghani, A	1
Alsahow, AE; Alsaran, K; Atia, M; El-Shafey, EM; Sabry, AA	1
Block, GA; Bushinsky, DA; Chertow, GM; Goodman, WG; Knight, TG; Lu, ZJ; Xu, X	1
Akizawa, T; Mizobuchi, M; Nakazawa, A	1
Fukagawa, M; Kakuta, T; Koizumi, M; Komaba, H; Sawada, K; Takahashi, H; Tanaka, H	1
Carsi, M; Chiroli, S; Iannazzo, S	1
Youssef, D	1
Belozeroff, V; Boer, R; Lalla, AM	1
Amdahl, M; Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Marx, S; Sharma, A; Wolf, M	1
Brzosko, S; Hryszko, T; Koc-Żórawska, E; Myśliwiec, M; Naumnik, B; Rydzewska-Rosołowska, A	1
Karohl, C; Raggi, P	1
Fukagawa, M; Goto, S; Kakuta, T; Kamae, I; Komaba, H; Moriwaki, K; Taniguchi, M; Yamada, S	1
Block, GA; Chertow, GM; Correa-Rotter, R; Drueke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Mix, TC; Moe, SM; Parfrey, PS; Wheeler, DC	1
Bratkowska, K; Chrul, S; Dryja, P; Nykiel, P; Pietrzak, B; Sek-Szczepanowska, K; Zwiech, R; Łacina, D	1
Fliser, D; Heine, GH; Ketteler, M; Seiler, S	1
Hu, B; Hu, P; Lu, L; Qin, YH; Wang, J; Xuan, Q	1
Fathallah-Shaykh, S; Langman, CB; Lee, E; Padhi, D; Posvar, E; Salusky, IB; Wang, C; Warady, BA	1
Castelnovo, C; Messa, P; Scalamogna, A	1
Tse, MT	1
Jiang, W; Li, D; Shao, L; Xu, Y; Zhang, W; Zhou, H	1
Brancaccio, D; Cannella, G; Cornago, D; Costanzo, AM; Cozzolino, M; Di Luca, M; di Luzio Paparatti, U; Mazzaferro, S; Messa, P; Morosetti, M; Roggeri, DP	1
Grzegorzewska, AE; Niepolski, L	1
Hosoya, T; Ishida, M; Iwamoto, T; Ohkido, I; Urashima, M; Yokoyama, K	1
Hashimoto, H; Hosoya, T; Ishida, M; Kimura, Y; Ohkido, I; Sekino, H; Shimada, H; Urae, J; Urashima, M; Yokoyama, K	1
Abbott, KC; Narayan, R; Nee, R; Yuan, CM	1
Bajo-Rubio, MA; De Sousa-Amorim, E; Del Peso-Gilsanz, G; Selgas-Gutiérrez, R	1
Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Hasegawa, T; Kurokawa, K; Onishi, Y; Yamaguchi, T	1
Akiba, T; Kikuchi, K; Nitta, K; Okano, K; Tsuruta, Y	1
Cai, MM; Holt, SG; McMahon, LP; Smith, ER; Williams, DS	1
Goretzki, PE; Lammers, BJ; Schwarz, K; Wirowski, D	1
Brunet, P; Fouque, D; Réglier, JC; Touam, M; Ureña, P	1
Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Torregrosa, JV	1
Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Soler, M; Torregrosa, JV	1
Floege, J; Goodman, WG; Hawley, CM; Pedagogos, E; Pétavy, F; Raggi, P; Reiner, M; Ureña-Torres, PA	1
Sunder, S; Venkataramanan, K; Verma, H	1
Neal, B; Perkovic, V	1
Block, GA; Chertow, GM; Correa-Rotter, R; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Mix, TC; Moe, SM; Parfrey, PS; Trotman, ML; Wheeler, DC	1
Chen, J; Gu, Y; Hao, C; Li, H; Li, M; Ni, L; You, L; Zhang, Q	1
Barros, X; Campistol, JM; Durán, CE; Paschoalin, RP; Sánchez-Escuredo, A; Torregrosa, JV	1
Chudek, J; Kocełak, P; Olszanecka Glinianowicz, M; Zelaźnicka, M	1
Bain, JH; Csongrádi, É; Fülöp, T; Hamrahian, M; Kanyicska, B; Pitman, KT	1
Hasegawa, E; Hattori, Y; Hayami, N; Hiramatsu, E; Hoshino, J; Marui, Y; Nagasawa, M; Nakamura, M; Sawa, N; Sumida, K; Suwabe, T; Takaichi, K; Tomikawa, S; Tsukamoto, M; Ubara, Y; Yamanouchi, M	1
Chrul, S; Zwiech, R	1
Bridges, I; Christiano, C; Cooper, K; Cournoyer, SH; Covic, A; Farouk, M; Kopyt, NP; Rodriguez, M; Ureña-Torres, P; Zehnder, D	1
Choi, KB; Choi, KH; Hwang, SD; Kim, JK; Kim, SW; Kim, YH; Kwon, YJ; Park, CW	1
Cooper, K; Farouk, M; Goodman, WG; Pétavy, F; Rodriguez, M; Ureña-Torres, P	1
Blaisdell, PW; Brenner, RM; Coburn, JW; Goodman, WG; Lindberg, JS; Liu, W; Martin, KJ; Moe, SM; Sprague, SM; Turner, SA	1
Adler, S; Bushinsky, DA; Liu, W; McCary, LC; Quarles, LD; Rosansky, SJ; Sherrard, DJ; Turner, SA	1
Franceschini, N; Joy, MS; Kshirsagar, A	1
Goodman, WG	3
Benyahia, M; Fournier, A; Harbouche, L; Mansour, J; Moriniere, P; Presne, C	1
Cases, A	1
Abu-Alfa, AK; Avram, MM; Block, GA; Braun, J; Cohen, RM; Coyne, DW; Cunningham, J; de Francisco, AL; Drüeke, TB; Evenepoel, P; Fournier, A; Goodman, WG; Hercz, G; Locatelli, F; Martin, KJ; McCary, LC; Messa, P; Moe, SM; Olson, KA; Suranyi, MG; Turner, SA; Zani, VJ	1
Curhan, G	1
Akizawa, T; Hishida, A; Kanamaru, M; Koshikawa, S; Nagashima, S; Ohashi, N; Togawa, A; Uchida, E; Uematsu, T	1
Alam, MG; Kumar, J; Owda, AK	1
Chanard, J; Ureña Torres, PA	1
Ureña Torres, P	2
Franceschini, N; Joy, MS; Kshirsagar, AV	1
Fukagawa, M; Nishi, H	1
Ogata, H; Taguchi, S; Yamamoto, M	1
Hirose, M; Koiwa, F	1
Barman Balfour, JA; Scott, LJ	1
Moe, SM	1
Nagano, N	2
Matuszkiewicz-Rowińska, J	1
Colloton, M; Lacey, D; Martin, D; Miller, G; Shatzen, E; Stehman-Breen, C; Wada, M	1
Block, GA; Chertow, GM; Coburn, JW; Cunningham, J; Drüeke, TB; Goodman, WG; Martin, KJ; McCary, LC; Moe, SM; Olson, KA; Quarles, LD; Sherrard, DJ; Turner, SA	1
Albizem, MB; Borah, MF; Clark, RV; Coburn, JW; Culleton, B; Guo, MD; Husserl, FE; Klassen, PS; Lindberg, JS; Roger, SD; Shapiro, WB; Wong, G	1
Nagano, N; Nemeth, EF	1
de Francisco, AL	2
González, EA; Martin, KJ; Wood, C	1
Attaf, D; Drüeke, TB; Menoyo, V; Thebaud, HE; Touam, M	1
Lien, YH; Silva, AL; Whittman, D	1
Cattley, RC; Colloton, M; Henley, C; Lacey, D; Martin, D; Shatzen, E; Towler, DA	1
Lindberg, JS	1
Byrnes, CA; Shepler, BM	1
Quarles, LD	1
Charytan, C; Chonchol, M; Coburn, JW; Herman, J; Klassen, PS; Lien, YH; Liu, W; McCary, LC; Pichette, V	1
Adler, S; Albizem, MB; Bommer, J; Cunningham, J; Goodman, WG; Guo, MD; Moe, SM; Rosansky, SJ; Sprague, SM; Urena-Torres, P; Zani, VJ	1
Andrés, E; Ballarín, J; Barceló, P; Bover, J; Ortiz-Herbener, F	1
Chertow, GM; Cunningham, J; Danese, M; Klassen, P; Olson, K	1
Elder, GJ	1
Cunningham, J	2
Anders, HJ	1
de Vernejoul, MC; Legoupil, N; Ureña, P	1
Dong, BJ	1
Fournier, A; Harbouche, L; Monge, M; Shahapuni, I	1
Mosekilde, L; Nielsen, LR; Vestergaard, P	1
Fottner, C; Weber, MM	1
Abbassi, A; Chuong, VT; de Vernejoul, MC; Guédon, C; Roueff, S; Saint Georges, M; Ureña Torres, P	1
Innes, A; MacGregor, MS; MacKay, IG; Velasco, N	1
Craig, JC; Elder, G; Messa, P; Palmer, S; Strippoli, GF; Tong, A	1
Apostolou, T; Damianou, L; Drakopoulos, S; Hadjiconstantinou, V; Kotsiev, V	1
Drüeke, TB; Landais, P	1
Imanishi, Y; Inaba, M; Ishikawa, T; Ishimura, E; Kawata, T; Kobayashi, K; Komo, T; Miki, T; Nagano, N; Nishizawa, Y; Okuno, S; Onoda, N; Tahara, H; Takemoto, Y; Wada, M	1
Imanishi, Y; Inaba, M	1
Sułowicz, W	1
Ito, H; Kinugasa, E; Koiwa, F; Ogata, H	1
Fukagawa, M	1
Choukroun, G; Fournier, A; Massy, Z; Mazouz, H; Monge, M; Morinière, P; Oprisiu, R; Shahapuni, I; Westeel, PF	1
Argilés, A; Chong, G; Deleuze, S; Delmas, S; Garrigue, V; Mourad, G; Szwarc, I	1
Delsignore, A; Hepp, U; Hersberger, M; Huber, AR; Savoca, R; Serra, AL; Wüthrich, RP	1
Bell, S; Casey, L; Chonchol, M; Parker, M; Spiegel, DM	1
Dorsch, O	1
Arias, M; de Francisco, AL; Palomar, R; Piñera, C	1
Apostolou, T; Damianou, L; Dracopoulos, S; Hadjiconstantinou, V; Kaitsioti, H; Kollia, K; Kotsiev, V; Vougas, V	1
Nowack, R; Wachtler, P	1
Fukagawa, M; Nakanishi, S	2
Anderson, R; D'Souza, R; Garside, R; Mealing, S; Pitt, M; Stein, K	1
Augustine, JJ; Korman, NJ; Robinson, MR	1
Cincotta, E; Doshi, MD; El-Amm, JM; Gruber, SA; Losanoff, JE; Migdal, S; Morawski, K; Singh, A; Sternbauer, D; West, MS	1
Canaud, B; Torres, PU	1
Lauerwald, W; Unbehaun, R	1
Charra, B; Chazot, C; Jean, G	2
Hebert, K; Lazar, E; Poma, T; Stankus, N	1
Antonelli, M; Basile, C; Giammaria, B; Lomonte, C; Losurdo, N; Marchio, G	1
Anderson, R; D'Souza, R; Garside, R; Mealing, S; Pitt, M; Roome, C; Snaith, A; Stein, K; Welch, K	1
Akiba, T	1
Colin Forfar, J; Tilling, L	1
Harris, RZ; Padhi, D; Salfi, M; Sullivan, JT	1
Joy, MS; Karagiannis, PC; Peyerl, FW	1
Albizem, M; Block, GA; Chertow, GM; Correa-Rotter, R; Drueke, TB; Floege, J; Goodman, WG; Klassen, P; London, GM; Mahaffey, KW; Moe, SM; Olson, K; Parfrey, P; Pupim, LB; Wheeler, DC	1
Arruda, JA; Bahner, U; Block, GA; Corpier, C; Disney, A; Klassen, PS; Olson, KA; Schwanauer, LE; Soroka, SD; Sterrett, JR; Strom, J; Stummvoll, HK	1
Palmer, AJ; Ray, JA; Valentine, WJ	1
Bommer, J; Brancaccio, D; Coyne, D	1
Bergua, C; Cofán, F; Oppenheimer, F; Torregrosa, JV	1
Bilezikian, JP; Martin, D; Wüthrich, RP	1
Bajo, MA; Codoceo, R; Del Peso, G; Díez, JJ; Gancedo, PG; Gil, F; Iglesias, P; Martinez-Ara, J; Miguel, JL; Sánchez, C; Selgas, R	1
Fukumoto, S	1
Cohen, E	1
Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H	1
Burnier, M; Pruijm, MT; Santschi, V; Teta, D; Wuerzner, G	1
Heller, T; Koziolek, MJ; Maass, E; Mueller, GA	1
Kazama, JJ	1
Hanba, Y; Negi, S; Ooura, M; Shigematsu, T	1
Comte, C; Dereure, O; Leray-Mouragues, H; Pallure, V	1
Bos, WJ; Bouman, K; Braun, J; Brink, H; Carter, D; Frazão, JM; Graf, H; Locatelli, F; Macário, F; Maduell, F; Messa, P; Molemans, B; Reichel, H; Saha, H; Torregrosa, V; von Albertini, B; Wilkie, M; Yaqoob, M; Zani, VJ	1
Chattopadhyay, N; Mithal, A; Trivedi, R	1
Alon, US; Levy-Olomucki, R; Liu, S; Moore, WV; Quarles, LD; Stubbs, J	1
Ahokas, RA; Bhattacharya, SK; Gerling, IC; Selektor, Y; Sun, Y; Weber, KT	1
Kher, KK; Khurana, M; Moudgil, A; Moylan, K; Silverstein, DM; Wilcox, J	1
Block, GA; Bushinsky, DA; Chertow, GM; Chi, EM; Sugihara, J; Turner, SA; Zeig, S	1
Iseki, K	1
Braun, SC; Corti, N; Hersberger, M; Russmann, S; Savoca, R; Serra, AL; Starke, A; Wüthrich, RP	1
Basile, C; Bruno, A; Cazzato, F; Chimienti, D; Cocola, S; Lomonte, C; Teutonico, A; Vernaglione, L	1
Akiba, T; Akizawa, T; Iwasaki, M; Koshikawa, S; Tsukamoto, Y; Uchida, E	1
Pedrini, LA; Ruggiero, P; Zerbi, S	1
Limardo, M; Locatelli, F; Pontoriero, G	1
Baker, N; Charytan, C; Coburn, JW; Coyne, DW; Frazã O, JM; Goodman, WG; Kaplan, MR; Malluche, HH; McCary, LC; Monier-Faugere, MC; Turner, SA; Wang, G	1
Bonny, O; Burnier, M	1
Brancaccio, D; Cozzolino, M; Fallabrino, G; Galassi, A; Gallieni, M; Pasho, S	1
Coyne, DW	1
Drueckler, E; Fischer, DC; Haffner, D; Kundt, G; Muscheites, J; Wigger, M	1
de Francisco, AL; Palomar, R; Piñera, C	1
Barri, YM; Blaisdell, PW; Coburn, JW; Cohen, RM; Goodkin, DA; Goodman, WG; Hladik, GA; Liu, W; Turner, SA	1

Reviews

122 review(s) available for cinacalcet and Hyperparathyroidism, Secondary

Article	Year
A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD). European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:1 Topics: Calcitriol; Calcium; Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic	2022
Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients. Current osteoporosis reports, 2023, Volume: 21, Issue:2 Topics: Adult; Calcimimetic Agents; Calcium; Cardiovascular Diseases; Child; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Minerals; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D	2023
Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review. Frontiers in endocrinology, 2023, Volume: 14 Topics: Calcimimetic Agents; Calcium; Child; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Machine Learning; Phosphates; United States	2023
Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials. International urology and nephrology, 2019, Volume: 51, Issue:11 Topics: Calcimimetic Agents; Cinacalcet; Drug Combinations; Humans; Hyperparathyroidism, Secondary; Randomized Controlled Trials as Topic; Renal Dialysis; Vitamin D; Vitamins	2019
Sensing Extracellular Calcium - An Insight into the Structure and Function of the Calcium-Sensing Receptor (CaSR). Advances in experimental medicine and biology, 2020, Volume: 1131 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney; Parathyroid Glands; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic	2020
Cinacalcet Treatment Significantly Improves All-Cause and Cardiovascular Survival in Dialysis Patients: Results from a Meta-Analysis. Kidney & blood pressure research, 2019, Volume: 44, Issue:6 Topics: Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Renal Dialysis; Survival Rate	2019
Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis. Pediatric nephrology (Berlin, Germany), 2020, Volume: 35, Issue:9 Topics: Adolescent; Calcimimetic Agents; Child; Child, Preschool; Cinacalcet; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Equivalence Trials as Topic; Female; Humans; Hyperparathyroidism, Secondary; Male; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic	2020
Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, Volume: 76, Issue:3 Topics: Adult; Calcimimetic Agents; Calcium; Cardiovascular Diseases; Cinacalcet; Comorbidity; Female; Fractures, Bone; Heart Failure; Humans; Hyperparathyroidism, Secondary; Male; Mortality; Naphthalenes; Nausea; Parathyroid Hormone; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vomiting	2020
Development of evocalcet for unmet needs among calcimimetic agents. Expert review of endocrinology & metabolism, 2020, Volume: 15, Issue:5 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Japan; Naphthalenes; Phosphorus; Pyrrolidines; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic	2020
[Aortic valve replacement via J-shaped partial upper sternotomy: randomized trial, mid-term results]. Khirurgiia, 2020, Issue:7 Topics: Adult; Aged; Aortic Valve; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Minimally Invasive Surgical Procedures; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Retrospective Studies; Sternotomy; Treatment Outcome	2020
Parathyroidectomy or cinacalcet: Do we still not know the best option for graft function in kidney-transplanted patients? A meta-analysis. Surgery, 2021, Volume: 170, Issue:3 Topics: Calcimimetic Agents; Cinacalcet; Clinical Decision-Making; Delayed Graft Function; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Parathyroidectomy	2021
Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, Nov-01, Volume: 32, Issue:11 Topics: Calcimimetic Agents; Cinacalcet; Combined Modality Therapy; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroidectomy; Postoperative Period; Quality of Life	2017
Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. The British journal of surgery, 2017, Volume: 104, Issue:7 Topics: Calcimimetic Agents; Cinacalcet; Graft Survival; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Parathyroidectomy; Postoperative Complications; Renal Insufficiency, Chronic	2017
Parathyroid Nodular Hyperplasia and Responsiveness to Drug Therapy in Renal Secondary Hyperparathyroidism: An Open Question. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2018, Volume: 22, Issue:1 Topics: Calcimimetic Agents; Calcitriol; Calcium Channel Agonists; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid Glands; Treatment Outcome	2018
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. Scientific reports, 2018, 02-15, Volume: 8, Issue:1 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic	2018
Calcimimetics versus parathyroidectomy: What is preferable? International urology and nephrology, 2018, Volume: 50, Issue:7 Topics: Administration, Oral; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Parathyroidectomy; Prognosis; Renal Dialysis; Risk Assessment; Treatment Outcome	2018
Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis. Journal of comparative effectiveness research, 2018, Volume: 7, Issue:7 Topics: Adult; Aged; Bayes Theorem; Calcimimetic Agents; Cinacalcet; Female; Fractures, Spontaneous; Hospitalization; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Observational Studies as Topic; Parathyroidectomy; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome	2018
Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. Drug design, development and therapy, 2018, Volume: 12 Topics: Calcimimetic Agents; Cinacalcet; Clinical Trials as Topic; Fibroblast Growth Factor-23; Humans; Hyperparathyroidism, Secondary; Medication Adherence; Peptides; Practice Guidelines as Topic; Renal Dialysis	2018
Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? Seminars in dialysis, 2018, Volume: 31, Issue:5 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Peptides	2018
Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:7 Topics: Bone and Bones; Calcimimetic Agents; Chelating Agents; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Medication Adherence; Naphthalenes; Receptors, Calcitriol; Renal Insufficiency, Chronic; Vitamin D	2013
Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality? The Netherlands journal of medicine, 2013, Volume: 71, Issue:7 Topics: Bone Density; Calcimimetic Agents; Calcinosis; Calcium; Cinacalcet; Heart Valve Diseases; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone	2013
Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. Renal failure, 2014, Volume: 36, Issue:1 Topics: Bone Density; Cardiovascular Diseases; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Naphthalenes; Practice Guidelines as Topic	2014
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? Current opinion in nephrology and hypertension, 2013, Volume: 22, Issue:6 Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic	2013
Management of hypercalcemia after renal transplantation. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2013, Nov-13, Volume: 33, Issue:6 Topics: Algorithms; Bone Resorption; Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Postoperative Complications; Renal Dialysis; Vitamin D	2013
[Gene polymorphism of the vitamin D receptor, vitamin D-binding protein and calcium-sensing receptor in respect of calcium-phosphate disturbances in chronic dialysis patients]. Przeglad lekarski, 2013, Volume: 70, Issue:9 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Phosphates; Polymorphism, Genetic; Receptors, Calcitriol; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D-Binding Protein	2013
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. The Cochrane database of systematic reviews, 2014, Issue:12 Topics: Calcimimetic Agents; Calcium; Cardiovascular Diseases; Cause of Death; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis	2014
Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control. Seminars in nephrology, 2014, Volume: 34, Issue:6 Topics: Bone and Bones; Calcimimetic Agents; Cinacalcet; Gastrointestinal Tract; Homeostasis; Humans; Hyperparathyroidism, Secondary; Hypertension, Pulmonary; Naphthalenes; Parathyroid Hormone; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Signal Transduction; Vascular Calcification; Water-Electrolyte Balance	2014
The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet. Expert review of pharmacoeconomics & outcomes research, 2015, Volume: 15, Issue:4 Topics: Adult; Chelating Agents; Cinacalcet; Cost-Benefit Analysis; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Phosphates; Vitamin D	2015
Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. Clinical journal of the American Society of Nephrology : CJASN, 2016, Jan-07, Volume: 11, Issue:1 Topics: Calcimimetic Agents; Cinacalcet; Electrocardiography; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Failure, Chronic; Parathyroid Hormone; Renal Dialysis; Vascular Calcification	2016
Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical journal of the American Society of Nephrology : CJASN, 2016, Mar-07, Volume: 11, Issue:3 Topics: Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Research Design; Risk Factors; Treatment Outcome	2016
Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:10 Topics: Bone Diseases, Metabolic; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Minerals; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D	2016
Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Renal failure, 2016, Volume: 38, Issue:7 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Parathyroidectomy; Prospective Studies; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Survival Rate; Treatment Outcome	2016
CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today? Advances in chronic kidney disease, 2016, Volume: 23, Issue:4 Topics: Bicarbonates; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, Protein-Restricted; Fibroblast Growth Factor-23; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic; Vitamin D	2016
Etelcalcetide for the treatment of secondary hyperparathyroidism. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:5 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Peptides; Renal Dialysis	2017
Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Internal medicine (Tokyo, Japan), 2008, Volume: 47, Issue:11 Topics: Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Japan; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Vitamin D	2008
Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney international, 2008, Volume: 74, Issue:3 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Molecular Mimicry; Naphthalenes; Receptors, Calcium-Sensing	2008
Calcimimetics in CKD-results from recent clinical studies. Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:10 Topics: Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Kidney Transplantation; Naphthalenes; Renal Dialysis	2008
[Cinacalcet - an allosteric enhancer at the Ca2+-receptor]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:33 Topics: Calcium; Cinacalcet; Drug Monitoring; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Parathyroid Neoplasms; Receptors, Calcium-Sensing; Renal Dialysis	2008
[Clinical advances in vascular calcification]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2008, Volume: 28 Suppl 5 Topics: Aged; Animals; Atherosclerosis; Calcinosis; Chronic Disease; Cinacalcet; Coronary Artery Disease; Diabetes Complications; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Diseases; Mice; Mice, Knockout; Multicenter Studies as Topic; Naphthalenes; Polyamines; Randomized Controlled Trials as Topic; Renal Artery; Sevelamer; Tomography, Spiral Computed; Tomography, X-Ray Computed; Vascular Diseases	2008
[Diagnosis and therapy of primary hyperparathyreoidism]. MMW Fortschritte der Medizin, 2008, Nov-06, Volume: 150, Issue:45 Topics: Adenoma; Adult; Bone Density Conservation Agents; Calcium; Cinacalcet; Diagnosis, Differential; Diphosphonates; Diuretics; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Incidence; Minimally Invasive Surgical Procedures; Naphthalenes; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Prevalence; Sex Factors; Video-Assisted Surgery	2008
[Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost]. Clinical calcium, 2009, Volume: 19, Issue:4 Topics: Bone Diseases, Metabolic; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroidectomy; Policy Making; Polyamines; Sevelamer; Vitamin D	2009
[Chronic kidney disease (CKD) and bone. The clinical perspective of parathyroid interventional therapy for advanced secondary hyperparathyroidism in the era of cinacalcet HCl]. Clinical calcium, 2009, Volume: 19, Issue:4 Topics: Chronic Disease; Cinacalcet; Drug Therapy, Combination; Ethanol; Humans; Hyperparathyroidism, Secondary; Injections, Intralesional; Kidney Diseases; Naphthalenes; Parathyroidectomy; Renal Dialysis; Vitamin D	2009
Calcimimetics in the chronic kidney disease-mineral and bone disorder. The International journal of artificial organs, 2009, Volume: 32, Issue:2 Topics: Bone Diseases; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes	2009
Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U". Clinical nephrology, 2009, Volume: 71, Issue:6 Topics: Calcium; Cinacalcet; Clinical Trials as Topic; Comorbidity; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcitriol; Treatment Outcome; Vitamins	2009
Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clinical pharmacokinetics, 2009, Volume: 48, Issue:5 Topics: Animals; Cinacalcet; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes	2009
Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease. Drugs & aging, 2009, Volume: 26, Issue:6 Topics: Aged; Chelating Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphates; Practice Guidelines as Topic; Receptors, Calcitriol; Renal Insufficiency, Chronic	2009
Management of mineral and bone disorder in chronic kidney disease: quo vadis? Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2009, Volume: 13 Suppl 1 Topics: Bone Diseases, Metabolic; Cinacalcet; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Vitamin D; Vitamins	2009
Cinacalcet in hyperfunctioning parathyroid diseases. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2009, Volume: 13 Suppl 1 Topics: Animals; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Receptors, Calcium-Sensing; Renal Dialysis; Uremia	2009
New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. Pediatric nephrology (Berlin, Germany), 2010, Volume: 25, Issue:4 Topics: Bone Density Conservation Agents; Calcium; Chelating Agents; Child; Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Glands; Phosphates; Polyamines; Protein Binding; Receptors, Calcitriol; Receptors, Calcium-Sensing; Sevelamer	2010
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline]. Clinical calcium, 2010, Volume: 20, Issue:7 Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic	2010
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD]. Clinical calcium, 2010, Volume: 20, Issue:7 Topics: Bone Diseases, Metabolic; Calcinosis; Calcium; Chronic Disease; Cinacalcet; Clinical Trials as Topic; Drug Therapy, Combination; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Vascular Diseases; Vitamin D	2010
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients]. Clinical calcium, 2010, Volume: 20, Issue:7 Topics: Bone Diseases, Metabolic; Calcitriol; Chelating Agents; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroidectomy; Polyamines; Practice Guidelines as Topic; Receptors, Calcium-Sensing; Sevelamer; Uremia; Vitamin D	2010
Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic. Nature reviews. Nephrology, 2011, Volume: 7, Issue:4 Topics: Cinacalcet; Graft Survival; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Nephrocalcinosis; Postoperative Complications; Transplantation, Homologous	2011
[Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives]. Nephrologie & therapeutique, 2011, Volume: 7, Issue:2 Topics: Biomarkers; Calcimimetic Agents; Calcium Phosphates; Cinacalcet; Evidence-Based Medicine; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Receptors, Calcium-Sensing; Renal Dialysis; Treatment Outcome	2011
Clinical utilization of cinacalcet in hypercalcemic conditions. Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:4 Topics: Calcimimetic Agents; Cinacalcet; Clinical Trials as Topic; Drug Evaluation; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Kidney Transplantation; Naphthalenes; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Receptors, Calcium-Sensing; Renal Dialysis	2011
Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease. PharmacoEconomics, 2011, Volume: 29, Issue:9 Topics: Calcium; Cinacalcet; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis	2011
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD]. Clinical calcium, 2011, Volume: 21, Issue:12 Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D	2011
Cinacalcet: will it play a role in reducing cardiovascular events? Future cardiology, 2012, Volume: 8, Issue:3 Topics: Calcimimetic Agents; Cardiomyopathies; Cardiovascular Diseases; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Myocytes, Cardiac; Naphthalenes	2012
Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease. International journal of biological sciences, 2012, Volume: 8, Issue:5 Topics: Animals; Calcimimetic Agents; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Endothelium, Vascular; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Kidney Transplantation; Male; Naphthalenes; Parathyroid Hormone; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification; Vitamin D; Vitamin D Deficiency	2012
Calcimimetics in peritoneal dialysis patients. Contributions to nephrology, 2012, Volume: 178 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Peritoneal Dialysis	2012
The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis. Endocrine, 2013, Volume: 43, Issue:1 Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcification, Physiologic; Calcimimetic Agents; Calcium, Dietary; Chelating Agents; Cinacalcet; Combined Modality Therapy; Dietary Supplements; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Peritoneal Dialysis; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Vitamin D	2013
[Calcimimetic drugs in stage 3-5 chronic kidney disease]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:190 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes	2012
[Kidney and bone update : the 5-year history and future of CKD-MBD. Parathyroidectomy for secondary hyperparathyroidism]. Clinical calcium, 2012, Volume: 22, Issue:7 Topics: Chronic Disease; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Japan; Kidney Diseases; Naphthalenes; Parathyroidectomy; Practice Guidelines as Topic	2012
Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PloS one, 2012, Volume: 7, Issue:10 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Odds Ratio; Patient Safety; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Treatment Outcome	2012
[Cinacalcet therapy and cardiovascular risk in hemodialysis patients]. Postepy higieny i medycyny doswiadczalnej (Online), 2012, Oct-22, Volume: 66 Topics: Atherosclerosis; Cardiovascular Diseases; Causality; Cinacalcet; Comorbidity; Disease Progression; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Renal Dialysis; Risk Factors; Vascular Calcification	2012
Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism. Expert opinion on investigational drugs, 2003, Volume: 12, Issue:8 Topics: Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Randomized Controlled Trials as Topic; Receptors, Calcium-Sensing; Receptors, Cell Surface	2003
Cinacalcet: AMG 073, Calcimimetics--Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493. Drugs in R&D, 2003, Volume: 4, Issue:6 Topics: Chronic Disease; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes	2003
Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatric nephrology (Berlin, Germany), 2003, Volume: 18, Issue:12 Topics: Aniline Compounds; Child; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing	2003
Calcimimetics versus vitamin D: what are their relative roles? Blood purification, 2004, Volume: 22, Issue:1 Topics: Calcitriol; Cinacalcet; Clinical Trials as Topic; Drug Synergism; Ergocalciferols; Humans; Hydroxycholecalciferols; Hypercalcemia; Hyperparathyroidism, Secondary; Intestinal Absorption; Kidney Failure, Chronic; Liver; Naphthalenes; Phosphates; Receptors, Calcitriol; Receptors, Calcium-Sensing; Vitamin D; Vitamin D Deficiency	2004
Update in nephrology. Highlights from the 36th Annual Meeting of the American Society of Nephrology. Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40, Issue:1 Topics: Anemia; Chronic Disease; Cinacalcet; Clinical Trials as Topic; Congresses as Topic; Diabetic Nephropathies; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Nephrology	2004
Calcimimetics and the treatment of primary and secondary hyperparathyroidism. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:11 Topics: Aniline Compounds; Animals; Cinacalcet; Half-Life; Humans; Hyperparathyroidism, Secondary; Metabolic Clearance Rate; Naphthalenes; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic; Rats	2004
Calcimimetic agents for the treatment of secondary hyperparathyroidism. Seminars in nephrology, 2004, Volume: 24, Issue:5 Topics: Aniline Compounds; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Phenethylamines; Propylamines	2004
[Clinical application of calcimimetics]. Clinical calcium, 2004, Volume: 14, Issue:5 Topics: Calcium; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Receptors, Calcium-Sensing	2004
[Prophylaxis and treatment of adynamic bone]. Clinical calcium, 2004, Volume: 14, Issue:9 Topics: Animals; Bone and Bones; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Calcium; Carrier Proteins; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Epoxy Compounds; Glycoproteins; Humans; Hyperparathyroidism, Secondary; Membrane Glycoproteins; Naphthalenes; Osteoprotegerin; Parathyroid Hormone; Polyamines; Polyethylenes; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Calcitriol; Receptors, Calcium-Sensing; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Risk; Sevelamer; Transforming Growth Factor beta; Vitamin D	2004
[Significance of point of no return in therapeutic strategy for treatment of renal osteodystrophy; from histopathological findings]. Clinical calcium, 2004, Volume: 14, Issue:9 Topics: Biomarkers; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Down-Regulation; Ethanol; Humans; Hyperparathyroidism, Secondary; Injections, Intralesional; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroidectomy; Receptors, Calcitriol; Receptors, Calcium-Sensing; Vitamin D	2004
Cinacalcet hydrochloride. Drugs, 2005, Volume: 65, Issue:2 Topics: Animals; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Neoplasms	2005
[Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion]. Clinical calcium, 2005, Volume: 15, Issue:1 Topics: Animals; Calcium; Cinacalcet; Clinical Trials as Topic; Depression, Chemical; Genes, Dominant; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Mutation; Naphthalenes; Parathyroid Hormone; Phosphorus; Rats; Receptors, Calcium-Sensing	2005
Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means. Pediatric nephrology (Berlin, Germany), 2005, Volume: 20, Issue:3 Topics: Animals; Child; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2005
[New aspects in the management of renal osteodystrophy]. Polskie Archiwum Medycyny Wewnetrznej, 2004, Volume: 112 Spec No Topics: Calcinosis; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Controlled Clinical Trials as Topic; Epoxy Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Phosphates; Polyamines; Polyethylenes; Sevelamer	2004
Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. Journal of pharmacological sciences, 2005, Volume: 97, Issue:3 Topics: Aniline Compounds; Animals; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Models, Biological; Molecular Structure; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Propylamines; Rats; Receptors, Calcium-Sensing	2005
Secondary hyperparathyroidism: review of the disease and its treatment. Clinical therapeutics, 2004, Volume: 26, Issue:12 Topics: Calcium; Cinacalcet; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Renal Dialysis	2004
Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney international. Supplement, 2005, Issue:95 Topics: Aniline Compounds; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Phenethylamines; Propylamines; Vitamin D	2005
Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis. Pharmacotherapy, 2005, Volume: 25, Issue:5 Topics: Cinacalcet; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Renal Dialysis	2005
Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? Current opinion in nephrology and hypertension, 2005, Volume: 14, Issue:4 Topics: Animals; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Glands; Parathyroid Hormone	2005
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney international. Supplement, 2005, Issue:96 Topics: Chronic Disease; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Practice Guidelines as Topic; Receptors, Calcium-Sensing	2005
[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25 Suppl 2 Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Calcium; Cinacalcet; Diphosphonates; Drug Therapy, Combination; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Retrospective Studies; Teriparatide; Transforming Growth Factor beta; Vitamin D	2005
Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacology & therapeutics, 2006, Volume: 109, Issue:3 Topics: Aniline Compounds; Animals; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Phenethylamines; Propylamines; Receptors, Calcium-Sensing	2006
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney international, 2005, Volume: 68, Issue:4 Topics: Adult; Aged; Cardiovascular Diseases; Cinacalcet; Female; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Quality of Life; Randomized Controlled Trials as Topic; Risk Factors	2005
Parathyroidectomy in the calcimimetic era. Nephrology (Carlton, Vic.), 2005, Volume: 10, Issue:5 Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroidectomy; Practice Guidelines as Topic; Risk Factors	2005
[Management of secondary hyperparathyroidism]. Clinical calcium, 2005, Volume: 15 Suppl 1 Topics: Aniline Compounds; Calcinosis; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phenethylamines; Phosphorus; Polyamines; Practice Guidelines as Topic; Propylamines; Receptors, Calcium-Sensing; Sevelamer; Vascular Diseases; Vitamin D	2005
[Chronic kidney disease]. Medizinische Klinik (Munich, Germany : 1983), 2005, Nov-15, Volume: 100, Issue:11 Topics: Acidosis; Adult; Anemia, Aplastic; Cardiovascular Diseases; Cinacalcet; Disease Progression; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Hypertension; Kidney Failure, Chronic; Kidney Transplantation; Multicenter Studies as Topic; Naphthalenes; Parathyroid Hormone; Practice Guidelines as Topic; Risk Factors	2005
[Calcimimetics, mechanisms of action and therapeutic applications]. Presse medicale (Paris, France : 1983), 2005, Sep-10, Volume: 34, Issue:15 Topics: Aniline Compounds; Animals; Bone Remodeling; Calcium; Cells, Cultured; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Hyperplasia; Male; Middle Aged; Multicenter Studies as Topic; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroid Neoplasms; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic; Rats; Receptors, Calcium-Sensing; Renal Dialysis; Risk Factors; Time Factors; Uremia	2005
Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clinical therapeutics, 2005, Volume: 27, Issue:11 Topics: Animals; Area Under Curve; Calcium; Cinacalcet; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Half-Life; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Naphthalenes; Parathyroid Hormone; Parathyroid Neoplasms; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis	2005
[Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism]. Ugeskrift for laeger, 2006, Jan-03, Volume: 168, Issue:1 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Parathyroid Neoplasms; Receptors, Calcium-Sensing; Uremia	2006
[The latest developments in endocrinology 2004/2005]. Medizinische Klinik (Munich, Germany : 1983), 2006, Jan-15, Volume: 101, Issue:1 Topics: Adrenal Gland Neoplasms; Adult; Bone Density Conservation Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Clinical Trials as Topic; Endocrinology; Eplerenone; Female; Humans; Hyperaldosteronism; Hyperparathyroidism; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Hypogonadism; Hypothyroidism; Male; Naphthalenes; Neuroendocrine Tumors; Organometallic Compounds; Osteoporosis, Postmenopausal; Pheochromocytoma; Positron-Emission Tomography; Pregnancy; Radiography, Abdominal; Spironolactone; Teriparatide; Testosterone; Testosterone Congeners; Thiophenes; Time Factors; Tomography, X-Ray Computed	2006
Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 47, Issue:5 Topics: Aniline Compounds; Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Phenethylamines; Propylamines; Randomized Controlled Trials as Topic	2006
[Secondary hyperparathyroidism]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Jun-28, Volume: Suppl 2 Topics: Adsorption; Blood Vessels; Calcinosis; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diagnosis, Differential; Ethanol; Humans; Hyperparathyroidism, Secondary; Injections, Intralesional; Kidney Failure, Chronic; Naphthalenes; Osteitis; Parathyroidectomy; Phosphorus; Prognosis; Renal Dialysis; Vitamin D	2006
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2006, Volume: 16, Issue:3 Topics: Calcium; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroid Neoplasms; Phosphates; Randomized Controlled Trials as Topic; Receptors, Calcium-Sensing; Renal Dialysis; Vitamin D	2006
[Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics]. Przeglad lekarski, 2006, Volume: 63 Suppl 3 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphates; Receptors, Calcium-Sensing; Renal Dialysis	2006
Therapeutic strategies for secondary hyperparathyroidism in dialysis patients. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2006, Volume: 10, Issue:4 Topics: Calcium; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Phosphates; Renal Dialysis; Vitamin D	2006
Drug Insight: renal indications of calcimimetics. Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:6 Topics: Calcium; Cinacalcet; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Naphthalenes; Parathyroid Neoplasms; Renal Dialysis	2006
Impact of treatment with calcimimetics on hyperparathyroidism and vascular mineralization. Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:12 Suppl 3 Topics: Calcinosis; Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Vascular Diseases	2006
[Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. Clinical calcium, 2007, Volume: 17, Issue:1 Topics: Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Mutation; Naphthalenes; Parathyroid Hormone; Parathyroid Neoplasms; Receptors, Calcium-Sensing	2007
The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2007, Volume: 11, Issue:18 Topics: Cardiovascular Diseases; Cinacalcet; Cost-Benefit Analysis; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Markov Chains; Middle Aged; Models, Economic; Naphthalenes; Parathyroid Hormone; Phosphates; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Calcium-Sensing; Renal Dialysis; Vitamin D	2007
[New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure]. Clinical calcium, 2007, Volume: 17, Issue:5 Topics: Bone Density Conservation Agents; Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Vitamin D	2007
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. Journal of managed care pharmacy : JMCP, 2007, Volume: 13, Issue:5 Topics: Calcitriol; Cardiovascular Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Cost-Benefit Analysis; Drug Costs; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Renal Insufficiency, Chronic; Vitamin D; Vitamins	2007
Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. Drugs, 2007, Volume: 67, Issue:14 Topics: Animals; Bone Density Conservation Agents; Calcitriol; Chronic Disease; Cinacalcet; Ergocalciferols; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Receptors, Calcitriol; Vitamin D	2007
The role of calcimimetics in the treatment of hyperparathyroidism. European journal of clinical investigation, 2007, Volume: 37, Issue:12 Topics: Adenoma; Calcium; Cinacalcet; Humans; Hyperparathyroidism; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy	2007
[Parathyroid and bone. Calcimimetics and bone metabolism]. Clinical calcium, 2007, Volume: 17, Issue:12 Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Cinacalcet; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Osteitis Fibrosa Cystica; Parathyroid Hormone; Randomized Controlled Trials as Topic; Rats; Receptors, Calcium-Sensing	2007
CKD-MBD: impact on management of kidney disease. Clinical and experimental nephrology, 2007, Volume: 11, Issue:4 Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins	2007
[Basic and clinical aspects of calcimimetics. Cinacalcet, effect and mechanisms of action]. Clinical calcium, 2008, Volume: 18, Issue:1 Topics: Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Glands; Receptors, Calcium-Sensing	2008
[Basic and clinical aspects of calcimimetics. The JSDT guideline and cinacalcet hydrochloride]. Clinical calcium, 2008, Volume: 18, Issue:1 Topics: Cinacalcet; Guidelines as Topic; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Receptors, Calcium-Sensing	2008
[Basic and clinical aspects of calcimimetics. Calcimimetics : a promising treatment for persistent hypercalcemia after kidney transplantation]. Clinical calcium, 2008, Volume: 18, Issue:1 Topics: Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Naphthalenes; Postoperative Complications; Receptors, Calcium-Sensing	2008
[Basic and clinical aspects of calcimimetics. Calcimimetics and vascular calcification]. Clinical calcium, 2008, Volume: 18, Issue:1 Topics: Animals; Blood Vessels; Calcinosis; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Rats; Receptors, Calcium-Sensing	2008
Recent updates on the calcium-sensing receptor as a drug target. Current medicinal chemistry, 2008, Volume: 15, Issue:2 Topics: Allosteric Regulation; Animals; Calcium; Cinacalcet; Clinical Trials as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Osteoporosis; Parathyroid Glands; Parathyroid Hormone; Receptors, Calcium-Sensing; Receptors, GABA-B	2008
Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:4 Topics: Calcinosis; Calcium; Chelating Agents; Cinacalcet; Coronary Artery Disease; Ethanol; Humans; Hyperparathyroidism, Secondary; Injections; Japan; Kidney Failure, Chronic; Naphthalenes; Niacinamide; Parathyroidectomy; Phosphates; Renal Dialysis; Treatment Outcome; Vitamin D	2008
New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:5 Topics: Animals; Calcium; Cinacalcet; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Transplantation; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Renal Insufficiency	2008
New approaches to treatment of secondary hyperparathyroidism. Current opinion in investigational drugs (London, England : 2000), 2008, Volume: 9, Issue:4 Topics: Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Phosphates; Receptors, Calcium-Sensing; Treatment Outcome; Vitamin D	2008
[Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet]. Revue medicale suisse, 2008, Mar-05, Volume: 4, Issue:147 Topics: Calcitriol; Chelating Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Polyamines; Renal Insufficiency; Sevelamer; Vitamin D Deficiency; Vitamins	2008
Preventive measures and new pharmacological approaches of calcium and phosphate disorders. Contributions to nephrology, 2008, Volume: 161 Topics: Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D	2008
Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nature clinical practice. Nephrology, 2008, Volume: 4, Issue:7 Topics: Animals; Cinacalcet; Contraindications; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Risk Factors; Severity of Illness Index	2008
Cinacalcet should be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nature clinical practice. Nephrology, 2008, Volume: 4, Issue:7 Topics: Animals; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Severity of Illness Index; Treatment Outcome	2008

Trials

102 trial(s) available for cinacalcet and Hyperparathyroidism, Secondary

Article	Year
Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism. PloS one, 2022, Volume: 17, Issue:12 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2022
Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, 07-31, Volume: 38, Issue:8 Topics: Adult; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroidectomy; Peritoneal Dialysis; Prospective Studies; Quality of Life; Renal Dialysis; Renal Insufficiency, Chronic	2023
Long-term results of a randomized study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism. Clinical transplantation, 2020, Volume: 34, Issue:8 Topics: Calcium; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Parathyroid Hormone; Parathyroidectomy; Retrospective Studies	2020
[Aortic valve replacement via J-shaped partial upper sternotomy: randomized trial, mid-term results]. Khirurgiia, 2020, Issue:7 Topics: Adult; Aged; Aortic Valve; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Minimally Invasive Surgical Procedures; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Retrospective Studies; Sternotomy; Treatment Outcome	2020
A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism. BMC nephrology, 2021, 03-23, Volume: 22, Issue:1 Topics: Adult; Calcinosis; Calcium-Regulating Hormones and Agents; Carotid Intima-Media Thickness; Cinacalcet; Heart Ventricles; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Middle Aged; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis	2021
A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. PharmacoEconomics, 2018, Volume: 36, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chelating Agents; Cinacalcet; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Health Care Costs; Humans; Hyperparathyroidism, Secondary; Markov Chains; Middle Aged; Models, Economic; Peptides; Quality-Adjusted Life Years; Vitamin D; Young Adult	2018
Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. Nutrients, 2018, Feb-10, Volume: 10, Issue:2 Topics: Aged; Bone Density; Calcifediol; Calcimimetic Agents; Calcitriol; Cholecalciferol; Cinacalcet; Dietary Supplements; Female; Femur Neck; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Severity of Illness Index; Vitamins	2018
Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney international, 2018, Volume: 93, Issue:6 Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Incidence; Male; Middle Aged; Renal Dialysis; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome	2018
Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 11-01, Volume: 34, Issue:11 Topics: Angiotensins; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Meta-Analysis as Topic; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Prognosis; Receptor, Angiotensin, Type 1; Renal Dialysis; Survival Rate	2019
Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney international, 2018, Volume: 94, Issue:4 Topics: Aged; Calcimimetic Agents; Cinacalcet; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic	2018
Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. Clinical drug investigation, 2018, Volume: 38, Issue:10 Topics: Adult; Area Under Curve; Asian People; Calcimimetic Agents; Cinacalcet; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hyperparathyroidism, Secondary; Male; Renal Insufficiency, Chronic; Single-Blind Method	2018
Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PloS one, 2018, Volume: 13, Issue:10 Topics: Administration, Oral; Aged; Calcimimetic Agents; Calcium; Cinacalcet; Combined Modality Therapy; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Renal Dialysis; Treatment Outcome	2018
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatric nephrology (Berlin, Germany), 2019, Volume: 34, Issue:3 Topics: Adolescent; Calcimimetic Agents; Calcium; Child; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Hypertension; Hypocalcemia; Male; Nausea; Parathyroid Hormone; Placebos; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vitamin D; Vomiting	2019
The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism. Renal failure, 2019, Volume: 41, Issue:1 Topics: Adult; Calcimimetic Agents; Calcium; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Treatment Outcome; Young Adult	2019
Pharmacodynamics of cinacalcet over 48 hours in patients with controlled secondary hyperparathyroidism: useful data in clinical practice. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Calcimimetic Agents; Cinacalcet; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Professional Practice; Renal Dialysis; Time Factors	2013
Cinacalcet improves endothelial dysfunction and cardiac hypertrophy in patients on hemodialysis with secondary hyperparathyroidism. Nephron. Clinical practice, 2012, Volume: 122, Issue:1-2 Topics: Cardiomegaly; Cinacalcet; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Prospective Studies; Renal Dialysis	2012
A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet. International urology and nephrology, 2014, Volume: 46, Issue:1 Topics: Adult; Aged; Alkaline Phosphatase; Calcimimetic Agents; Calcium; Cinacalcet; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Medication Adherence; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Pilot Projects; Prospective Studies; Renal Dialysis; Severity of Illness Index	2014
Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. Journal of medical economics, 2013, Volume: 16, Issue:9 Topics: Administration, Oral; Aged; Cinacalcet; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Ergocalciferols; Female; Follow-Up Studies; Health Care Costs; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Prospective Studies; Renal Dialysis; Treatment Outcome; Vitamin D	2013
Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet. Journal of medical economics, 2013, Volume: 16, Issue:9 Topics: Adult; Algorithms; Cinacalcet; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Renal Dialysis; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome; United States; Vitamin D	2013
Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: results of a prospective randomized controlled study. BioMed research international, 2013, Volume: 2013 Topics: Calcimimetic Agents; Causality; Cinacalcet; Comorbidity; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Medication Adherence; Middle Aged; Naphthalenes; Prevalence; Risk Factors; Switzerland; Treatment Outcome	2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:12 Topics: Adult; Aged; Bone Diseases, Metabolic; Calcimimetic Agents; Cinacalcet; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroidectomy; Proportional Hazards Models; Renal Dialysis; Severity of Illness Index	2013
Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. Clinical endocrinology, 2014, Volume: 80, Issue:4 Topics: Adult; Calcium; Cinacalcet; Depression, Chemical; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic	2014
Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study. The Journal of heart valve disease, 2013, Volume: 22, Issue:3 Topics: Aged; Bone Density Conservation Agents; Calcinosis; Cinacalcet; Coronary Vessels; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heart Valves; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Naphthalenes; Prognosis; Receptors, Calcium-Sensing; Renal Dialysis; Treatment Outcome; Vitamin D	2013
Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA. Clinical drug investigation, 2014, Volume: 34, Issue:2 Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density Conservation Agents; Cinacalcet; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Renal Dialysis; Treatment Outcome; United States; Vitamin D	2014
Impact of parathyroidectomy on serum FGF23 and soluble Klotho in hemodialysis patients with severe secondary hyperparathyroidism. The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:4 Topics: Aged; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Klotho Proteins; Male; Middle Aged; Naphthalenes; Parathyroidectomy; Postoperative Period; Renal Dialysis; Severity of Illness Index; Solubility	2014
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2014, Volume: 29, Issue:4 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Ergocalciferols; Female; Fibroblast Growth Factor-23; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome	2014
Effect of cinacalcet treatment on vascular arterial stiffness among peritoneal dialysis patients with secondary hyperparathyroidism. Nephrology (Carlton, Vic.), 2014, Volume: 19, Issue:6 Topics: Aged; Blood Flow Velocity; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peritoneal Dialysis; Pilot Projects; Prospective Studies; Pulsatile Flow; Treatment Outcome; Vascular Calcification; Vascular Stiffness	2014
Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney international, 2015, Volume: 87, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Osteogenesis; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Young Adult	2015
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. Journal of the American Heart Association, 2014, Nov-17, Volume: 3, Issue:6 Topics: Atherosclerosis; Calcimimetic Agents; Cinacalcet; Death, Sudden, Cardiac; Double-Blind Method; Female; Heart Failure; Humans; Hyperparathyroidism, Secondary; Intention to Treat Analysis; Kidney Failure, Chronic; Male; Naphthalenes; Renal Dialysis; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome	2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Journal of the American Society of Nephrology : JASN, 2015, Volume: 26, Issue:6 Topics: Adult; Age Factors; Aged; Cinacalcet; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Proportional Hazards Models; Reference Values; Renal Dialysis; Risk Assessment; Sex Factors; Statistics, Nonparametric; Treatment Outcome	2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clinical journal of the American Society of Nephrology : CJASN, 2015, May-07, Volume: 10, Issue:5 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Parathyroidectomy; Renal Dialysis; Severity of Illness Index	2015
Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2015, Volume: 19, Issue:4 Topics: Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Japan; Kidney Failure, Chronic; Male; Middle Aged; Organ Size; Parathyroid Glands; Parathyroid Hormone; Prognosis; Prospective Studies; Renal Dialysis; Risk Assessment; Severity of Illness Index; Time	2015
Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Clinical journal of the American Society of Nephrology : CJASN, 2015, Jun-05, Volume: 10, Issue:6 Topics: Aged; Australia; Biomarkers; Calcimimetic Agents; Calcium; Canada; Chi-Square Distribution; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Risk Factors; Russia; Time Factors; Treatment Outcome; United States; Vitamin D	2015
The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial. Clinical journal of the American Society of Nephrology : CJASN, 2015, May-07, Volume: 10, Issue:5 Topics: Adult; Aged; Blood Pressure; Body Mass Index; Calcimimetic Agents; Calciphylaxis; Cinacalcet; Dyslipidemias; Female; Humans; Hyperparathyroidism, Secondary; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Renal Dialysis; Risk Factors; Sex Factors; Vitamin K	2015
A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Clinical journal of the American Society of Nephrology : CJASN, 2015, Jun-05, Volume: 10, Issue:6 Topics: Aged; Aged, 80 and over; Australia; Biomarkers; Calcimimetic Agents; Canada; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Parathyroid Hormone; Prospective Studies; Renal Dialysis; Russia; Time Factors; Treatment Outcome; United States; Vitamin D	2015
A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism. Journal of the American Society of Nephrology : JASN, 2016, Volume: 27, Issue:8 Topics: Calcimimetic Agents; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Parathyroidectomy; Postoperative Complications; Prospective Studies	2016
Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2015, Volume: 18, Issue:8 Topics: Adult; Aged; Calcimimetic Agents; Cinacalcet; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Markov Chains; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Renal Dialysis; United States	2015
Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis. Hemodialysis international. International Symposium on Home Hemodialysis, 2016, Volume: 20, Issue:4 Topics: Asian People; Calcimimetic Agents; China; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis	2016
Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events. Medical decision making : an international journal of the Society for Medical Decision Making, 2016, Volume: 36, Issue:8 Topics: Adult; Aged; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Regression Analysis; Renal Dialysis; Research Design	2016
PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Scientific reports, 2016, Apr-13, Volume: 6 Topics: Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic	2016
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA, 2017, 01-10, Volume: 317, Issue:2 Topics: Administration, Oral; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Nausea; Parathyroid Hormone; Peptides; Renal Dialysis; Time Factors; Vomiting	2017
[Is autotransplantation with parathyroidectomy for secondary hyperparathyroidism outdated?] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2017, Volume: 88, Issue:4 Topics: Autografts; Cinacalcet; Combined Modality Therapy; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Parathyroid Glands; Parathyroidectomy; Pilot Projects; Postoperative Complications; Prospective Studies; Recurrence; Thymectomy	2017
[Cinacalcet in the therapy of secondary hyperparathyroidism--own experiences]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2008, Volume: 24, Issue:142 Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Treatment Outcome	2008
Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation, 2008, Aug-15, Volume: 86, Issue:3 Topics: Administration, Oral; Aged; Alkaline Phosphatase; Bone Density; Calcifediol; Calcitriol; Calcium; Cinacalcet; Creatinine; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Prospective Studies; Time Factors; Treatment Outcome	2008
Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. Clinical nephrology, 2008, Volume: 70, Issue:2 Topics: Administration, Oral; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Treatment Outcome	2008
Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. American journal of nephrology, 2009, Volume: 29, Issue:3 Topics: Adult; Aged; Bone and Bones; Bone Resorption; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Renal Dialysis; Treatment Outcome	2009
Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:6 Topics: Adult; Aged; Calcium; Chronic Disease; Cinacalcet; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Time Factors; Treatment Outcome; Vitamin D; Vitamins	2008
Change in coronary artery calcification score due to cinacalcet hydrochloride administration. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Calcinosis; Cinacalcet; Coronary Artery Disease; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Renal Dialysis; Time Factors; Treatment Outcome	2008
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:2 Topics: Aged; Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis	2009
Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:3 Topics: Adult; Aged; Cinacalcet; Cohort Studies; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Receptors, Calcium-Sensing; Renal Dialysis; Ultrasonography, Doppler, Color	2009
Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clinical journal of the American Society of Nephrology : CJASN, 2009, Volume: 4, Issue:3 Topics: Adult; Aged; Alkaline Phosphatase; Australia; Calcium; Cinacalcet; Double-Blind Method; Down-Regulation; Europe; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Time Factors; Treatment Outcome; United States	2009
Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet. Nephron. Clinical practice, 2009, Volume: 112, Issue:1 Topics: Adult; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Vitamin D	2009
Dual-phase 99mTc-MIBI scintigraphy to assess calcimimetic effect in patients on haemodialysis with secondary hyperparathyroidism. Nuclear medicine communications, 2009, Volume: 30, Issue:11 Topics: Adult; Aged; Biological Transport; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Radionuclide Imaging; Renal Dialysis; Technetium Tc 99m Sestamibi; Treatment Outcome	2009
Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clinical journal of the American Society of Nephrology : CJASN, 2009, Volume: 4, Issue:9 Topics: Adult; Aged; Biomarkers; Calcium; Canada; Chelating Agents; Chronic Disease; Cinacalcet; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peritoneal Dialysis; Phosphates; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome; United States; Vitamin D	2009
Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism? Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2009, Volume: 13 Suppl 1 Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Treatment Outcome	2009
Middle-term use of Cinacalcet in paediatric dialysis patients. Pediatric nephrology (Berlin, Germany), 2010, Volume: 25, Issue:1 Topics: Adolescent; Child; Child, Preschool; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Hypophosphatemia; Infant; Kidney Failure, Chronic; Male; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Retrospective Studies; Treatment Outcome	2010
Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size. Nephron. Clinical practice, 2010, Volume: 114, Issue:3 Topics: Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes; Organ Size; Parathyroid Glands; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Ultrasonography	2010
Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:6 Topics: Aged; Calcinosis; Cinacalcet; Coronary Artery Disease; Disease Progression; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Renal Dialysis; Vascular Diseases; Vitamin D	2010
Parathyroid gland ultrasound patterns and biochemical findings after one-year cinacalcet treatment for advanced secondary hyperparathyroidism. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2010, Volume: 14, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cinacalcet; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Prospective Studies; Radionuclide Imaging; Renal Dialysis; Severity of Illness Index; Time Factors; Ultrasonography	2010
Effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:8 Topics: Calcinosis; Cinacalcet; Coronary Artery Disease; Disease Progression; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Renal Dialysis; Treatment Outcome	2010
Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2010, Volume: 14, Issue:6 Topics: Aged; Cinacalcet; Drug Resistance; Female; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Prospective Studies; Renal Dialysis; Ultrasonography	2010
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:4 Topics: Adult; Calcinosis; Cinacalcet; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Prognosis; Prospective Studies; Renal Dialysis; Vitamin D; Vitamins	2011
[German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:4 Topics: Adult; Aged; Calcium Phosphates; Chelating Agents; Cinacalcet; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Prospective Studies; Renal Dialysis; Vitamin D	2011
[Effect of cinacalcet on parathyroid hormone level in hypercalcemic hyperparathyroidism of patients with renal transplantation]. Medicina clinica, 2012, Apr-07, Volume: 138, Issue:8 Topics: Adult; Biomarkers; Calcimimetic Agents; Cinacalcet; Collagen; Drug Administration Schedule; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Middle Aged; Naphthalenes; Parathyroid Hormone; Peptide Fragments; Treatment Outcome	2012
Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2011, Volume: 15 Suppl 1 Topics: Aged; Cinacalcet; Electrochemistry; Female; Humans; Hyperparathyroidism, Secondary; Immunoassay; Immunoradiometric Assay; Kidney Diseases; Luminescent Measurements; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2011
Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood purification, 2011, Volume: 32, Issue:2 Topics: Aged; Calcitriol; Cardiovascular Diseases; Cinacalcet; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Italy; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Odds Ratio; Prospective Studies; Renal Dialysis; Risk Factors; Survival Rate; Vitamins	2011
Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:2 Topics: Aged; Analysis of Variance; Biomarkers; Cinacalcet; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Linear Models; Logistic Models; Male; Middle Aged; Multivariate Analysis; Naphthalenes; Parathyroid Hormone; Prospective Studies; Renal Dialysis; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome	2012
Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns. Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:9 Topics: Aged; Calcium; Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Patterns, Physicians'; Renal Dialysis	2011
Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. International urology and nephrology, 2012, Volume: 44, Issue:5 Topics: Aged; Bone and Bones; Calcimimetic Agents; Cinacalcet; Collagen Type I; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Osteoblasts; Osteocalcin; Parathyroid Hormone; Peptides; Renal Dialysis; Renal Insufficiency, Chronic	2012
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcimimetic Agents; Cinacalcet; Cohort Studies; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Practice Guidelines as Topic; Renal Dialysis; Treatment Outcome; Vitamin D	2012
Efficacy and safety of cinacalcet for the treatment of secondary hyperparathyroidism in patients with advanced chronic kidney disease before initiation of regular dialysis. Nephrology (Carlton, Vic.), 2012, Volume: 17, Issue:1 Topics: Adult; Aged; Calcimimetic Agents; Calcium; Chronic Disease; Cinacalcet; Compassionate Use Trials; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Severity of Illness Index; Treatment Outcome; Vitamin D	2012
Does cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism, improve arterial stiffness in patients on continuous ambulatory peritoneal dialysis? Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, 2011, Volume: 27 Topics: Administration, Oral; Ankle Brachial Index; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Vascular Calcification; Vascular Stiffness	2011
Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2011, Volume: 15, Issue:6 Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Bone Density Conservation Agents; Chelating Agents; Cinacalcet; Female; Femur; Humans; Hyperparathyroidism, Secondary; Lumbar Vertebrae; Male; Middle Aged; Naphthalenes; Phosphorus; Prospective Studies; Pruritus; Renal Dialysis; Treatment Outcome; Vitamin D	2011
Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodialysis international. International Symposium on Home Hemodialysis, 2012, Volume: 16, Issue:2 Topics: Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Quality of Life; Renal Dialysis; Self Report; Surveys and Questionnaires; Treatment Outcome; Vitamin D	2012
Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:5 Topics: Aged; Calcimimetic Agents; Calcium; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Phosphorus; Renal Dialysis; Treatment Outcome	2012
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:8 Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vitamin D	2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:7 Topics: Australia; Bone Diseases; Calcimimetic Agents; Canada; Cardiovascular Diseases; Cinacalcet; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Minerals; Naphthalenes; Prognosis; Renal Dialysis; Russia; Survival Rate; United States; Vitamin D	2012
[The assessment of cynacalcet (Mimpara) accompanied by alfacalcidol treatment efficacy in haemodialysis patients with different secondary hyperparathyroidism severity recognized by iPTH]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2011, Volume: 64, Issue:4 Topics: Adult; Cinacalcet; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2011
An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. Pediatric nephrology (Berlin, Germany), 2012, Volume: 27, Issue:10 Topics: Administration, Oral; Adolescent; Age Factors; Area Under Curve; Biomarkers; Body Surface Area; Calcimimetic Agents; Calcium; Child; Cinacalcet; Drug Dosage Calculations; Female; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes; Parathyroid Hormone; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; United States	2012
Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:1 Topics: Aged; Cinacalcet; Disease Progression; Female; Humans; Hyperparathyroidism, Secondary; Male; Medication Adherence; Middle Aged; Naphthalenes; Renal Dialysis; Renal Insufficiency, Chronic; Vascular Calcification; Vitamin D	2013
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. The New England journal of medicine, 2012, Dec-27, Volume: 367, Issue:26 Topics: Adult; Aged; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Intention to Treat Analysis; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Odds Ratio; Parathyroid Hormone; Renal Dialysis	2012
Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:5 Topics: Adult; Aged; Calcium; Case-Control Studies; Cinacalcet; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; International Agencies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prognosis; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D; Vitamins	2013
Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients. The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:2 Topics: Adult; Aged; Calcitriol; Cinacalcet; Disease Progression; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Renal Dialysis; Treatment Outcome	2013
The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney international, 2003, Volume: 63, Issue:1 Topics: Adult; Aged; Calcitriol; Calcium; Calcium Channel Agonists; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Titrimetry	2003
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. Journal of the American Society of Nephrology : JASN, 2003, Volume: 14, Issue:3 Topics: Adult; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Receptors, Cell Surface; Renal Dialysis; Vitamin D	2003
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15 Topics: Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis	2004
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney international, 2005, Volume: 67, Issue:2 Topics: Adult; Aged; Bone and Bones; Calcium; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus	2005
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:3 Topics: Administration, Oral; Adult; Calcium; Cinacalcet; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peritoneal Dialysis; Phosphorus; Renal Dialysis; Vitamin D	2005
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 46, Issue:1 Topics: Calcium; Chronic Disease; Cinacalcet; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Treatment Outcome; Vitamin D	2005
Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:10 Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Time Factors	2005
Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:2 Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Calcium; Cinacalcet; Creatinine; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Prospective Studies; Quality of Life; Transplantation, Homologous; Treatment Outcome	2007
Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplantation proceedings, 2006, Volume: 38, Issue:10 Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Postoperative Complications	2006
Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism. American journal of nephrology, 2007, Volume: 27, Issue:3 Topics: Black or African American; Bone and Bones; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes	2007
Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clinical pharmacokinetics, 2007, Volume: 46, Issue:6 Topics: Administration, Oral; Adult; Analysis of Variance; Antifungal Agents; Area Under Curve; Calcium; Cinacalcet; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Half-Life; Humans; Hyperparathyroidism, Secondary; Ketoconazole; Male; Naphthalenes; Renal Insufficiency, Chronic	2007
Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clinical nephrology, 2007, Volume: 68, Issue:1 Topics: Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Renal Dialysis; Time Factors	2007
Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplantation proceedings, 2007, Volume: 39, Issue:7 Topics: Adult; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Patient Selection; Prospective Studies	2007
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Calcium; Chelating Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Treatment Outcome; Vitamin D	2008
Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:3 Topics: Administration, Oral; Adolescent; Calcitriol; Calcium; Child; Cinacalcet; Creatinine; Drug Administration Schedule; Drug Therapy, Combination; Familial Hypophosphatemic Rickets; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Genetic Diseases, X-Linked; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes; Nephrocalcinosis; Parathyroid Hormone; Phosphates; Potassium Compounds; Treatment Outcome; Vitamins	2008
Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:7 Topics: Adult; Aged; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Severity of Illness Index; Sterols; Treatment Outcome; Vitamin D	2008
Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12, Issue:2 Topics: Acid Phosphatase; Aged; Asian People; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Isoenzymes; Japan; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Osteocalcin; Parathyroid Hormone; Phosphorus; Renal Dialysis; Tartrate-Resistant Acid Phosphatase	2008
An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clinical nephrology, 2008, Volume: 69, Issue:4 Topics: Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Double-Blind Method; Female; Fibrosis; Humans; Hyperparathyroidism, Secondary; Ilium; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Prospective Studies; Renal Dialysis	2008
The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Journal of the American Society of Nephrology : JASN, 2002, Volume: 13, Issue:4 Topics: Administration, Oral; Adult; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Osmolar Concentration; Parathyroid Hormone; Renal Dialysis	2002

Other Studies

286 other study(ies) available for cinacalcet and Hyperparathyroidism, Secondary

Article	Year
The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Scientific reports, 2021, 09-09, Volume: 11, Issue:1 Topics: Age Factors; Aged; Alleles; Calcitriol; Calcium; Calcium-Regulating Hormones and Agents; Cinacalcet; Ergocalciferols; Female; Gene Expression; Genotype; Heterozygote; Homozygote; Humans; Hyperparathyroidism, Secondary; Logistic Models; Male; Middle Aged; Parathyroid Hormone; Phosphates; Polymorphism, Single Nucleotide; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies	2021
Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia. Journal of the American Society of Nephrology : JASN, 2022, Volume: 33, Issue:1 Topics: Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Middle Aged; Parathyroid Hormone; Peptides; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies	2022
A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride. CEN case reports, 2022, Volume: 11, Issue:2 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Peptides; Renal Dialysis	2022
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients. World journal of surgery, 2022, Volume: 46, Issue:4 Topics: Adult; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Parathyroid Hormone; Parathyroidectomy; Renal Dialysis; United States	2022
Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis. The Journal of clinical endocrinology and metabolism, 2022, 06-16, Volume: 107, Issue:7 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Parathyroidectomy; Prospective Studies; Renal Dialysis	2022
Increasing rates of parathyroidectomy to treat secondary hyperparathyroidism in dialysis patients with Medicare coverage. Surgery, 2022, Volume: 172, Issue:1 Topics: Adolescent; Adult; Aged; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Medicare; Middle Aged; Parathyroidectomy; Renal Dialysis; United States; Young Adult	2022
Effects of Cinacalcet and Parathyroidectomy on Blood Pressure in Maintenance Hemodialysis Patients with Secondary Hyperparathyroidism. Iranian journal of kidney diseases, 2022, Volume: 16, Issue:2 Topics: Blood Pressure; Calcitriol; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hypertension; Parathyroidectomy; Renal Dialysis; Retrospective Studies	2022
Impact of parathyroidectomy on kidney graft function in post-transplant tertiary hyperparathyroidism: a comparative study. Langenbeck's archives of surgery, 2022, Volume: 407, Issue:6 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney; Kidney Transplantation; Parathyroid Hormone; Parathyroidectomy	2022
Parathyroidectomy and Cinacalcet Use in Medicare-Insured Kidney Transplant Recipients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2023, Volume: 81, Issue:3 Topics: Aged; Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Medicare; Parathyroid Hormone; Parathyroidectomy; Retrospective Studies; United States	2023
Management of lithium-associated hyperparathyroidism with cinacalcet hydrochloride. British journal of hospital medicine (London, England : 2005), 2023, 01-02, Volume: 84, Issue:1 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Lithium; Parathyroid Hormone	2023
Long-term use of etelcalcetide for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis for end-stage renal failure: a real-life retrospective observational study. International urology and nephrology, 2023, Volume: 55, Issue:7 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone; Renal Dialysis	2023
PTH control and cardiovascular outcomes: does the treatment approach matter? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, 07-31, Volume: 38, Issue:8 Topics: Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroidectomy; Peritoneal Dialysis	2023
Pre-operative Cinacalcet Administration Reduces Immediate Post-operative Hypocalcemia Following Total Parathyroidectomy in Severe Renal Hyperparathyroidism. World journal of surgery, 2023, Volume: 47, Issue:8 Topics: Calcium; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism; Hyperparathyroidism, Secondary; Hypocalcemia; Parathyroid Hormone; Parathyroidectomy; Retrospective Studies; Treatment Outcome	2023
Resolution of Secondary Hyperparathyroidism After Kidney Transplantation and the Effect on Graft Survival. Annals of surgery, 2023, 09-01, Volume: 278, Issue:3 Topics: Calcium; Cinacalcet; Graft Survival; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Parathyroid Hormone; Parathyroidectomy; Retrospective Studies	2023
Discovery of LNP1892: A Precision Calcimimetic for the Treatment of Secondary Hyperparathyroidism. Journal of medicinal chemistry, 2023, 07-27, Volume: 66, Issue:14 Topics: Animals; Calcium; Cinacalcet; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Renal Insufficiency, Chronic	2023
Effects of evocalcet on parathyroid calcium-sensing receptor and vitamin D receptor expression in uremic rats. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2023, Volume: 37, Issue:8 Topics: Animals; Cinacalcet; Hyperparathyroidism, Secondary; Parathyroid Glands; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Receptors, Calcium-Sensing	2023
Treatment of Secondary Hyperparathyroidism and Posttransplant Tertiary Hyperparathyroidism. The Journal of surgical research, 2023, Volume: 291 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Parathyroidectomy; Renal Dialysis; Retrospective Studies	2023
New Insights into the Effects of Etelcalcetide on Bone Health. Clinical journal of the American Society of Nephrology : CJASN, 2023, 11-01, Volume: 18, Issue:11 Topics: Bone Density; Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Peptides; Renal Dialysis	2023
The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism. Jornal brasileiro de nefrologia, 2019, Jul-18, Volume: 41, Issue:3 Topics: Adult; Aged; Alkaline Phosphatase; Calcimimetic Agents; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vitamin D	2019
A Multi-Compartment Model Capturing the Pharmacokinetics of the Calcimimetic Cinacalcet. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2019, Volume: 53, Issue:2 Topics: Calcimimetic Agents; Cinacalcet; Computer Simulation; Humans; Hyperparathyroidism, Secondary; Liver; Models, Biological; Protein Binding; Renal Insufficiency, Chronic	2019
Successful management of tertiary hyperparathyroidism associated with hypophosphataemic rickets in an adult. Journal of musculoskeletal & neuronal interactions, 2019, 09-01, Volume: 19, Issue:3 Topics: Adult; Bone Density Conservation Agents; Calcium-Regulating Hormones and Agents; Cinacalcet; Familial Hypophosphatemic Rickets; Female; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Parathyroidectomy	2019
Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years . Clinical nephrology, 2019, Volume: 92, Issue:6 Topics: Calcimimetic Agents; Child, Preschool; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Infant; Kidney Failure, Chronic; Male; Peritoneal Dialysis; Renal Dialysis; Retrospective Studies	2019
Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020, 01-01, Volume: 35, Issue:1 Topics: Calcimimetic Agents; Child; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Evidence-Based Medicine; Humans; Hyperparathyroidism, Secondary; Practice Guidelines as Topic; Renal Dialysis	2020
Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. Journal of nephrology, 2020, Volume: 33, Issue:4 Topics: Aged; Calcium; Cinacalcet; Europe; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis	2020
Early response of the parathyroid gland to withdrawal of a calcimimetic compound in uremic rats. American journal of physiology. Renal physiology, 2020, 03-01, Volume: 318, Issue:3 Topics: Animals; Calcitriol; Cinacalcet; Hyperparathyroidism, Secondary; Male; Nephrectomy; Parathyroid Glands; Rats; Rats, Sprague-Dawley; Renal Insufficiency	2020
The use of cinacalcet after pediatric renal transplantation: an international CERTAIN Registry analysis. Pediatric nephrology (Berlin, Germany), 2020, Volume: 35, Issue:9 Topics: Adolescent; Calcimimetic Agents; Child; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Off-Label Use; Pilot Projects; Registries; Retrospective Studies; Transplant Recipients	2020
Surgical outcomes of parathyroidectomy for secondary hyperparathyroidism resistant to calcimimetic treatment: A retrospective single-center cohort study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2021, Volume: 25, Issue:2 Topics: Adult; Aged; Calcimimetic Agents; Cinacalcet; Cohort Studies; Drug Resistance; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Operative Time; Parathyroidectomy; Retrospective Studies; Treatment Outcome	2021
Calcimimetics: A Promise Unfulfilled. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, Volume: 76, Issue:3 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Network Meta-Analysis	2020
Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism. Pharmaceutical statistics, 2020, Volume: 19, Issue:6 Topics: Age Factors; Bayes Theorem; Biomarkers; Calcium; Cinacalcet; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Drug Development; Humans; Hyperparathyroidism, Secondary; Models, Statistical; Parathyroid Hormone; Research Design; Time Factors; Treatment Outcome	2020
Clinical evidence of direct bone effects of cinacalcet. Kidney international, 2020, Volume: 98, Issue:2 Topics: Bone and Bones; Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Renal Dialysis	2020
Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis. Surgery, 2021, Volume: 169, Issue:1 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Computer Simulation; Cost-Benefit Analysis; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Failure, Chronic; Medicare; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Parathyroidectomy; Quality-Adjusted Life Years; Renal Dialysis; Renal Elimination; Time-to-Treatment; United States	2021
Cost-effectiveness analysis of cinacalcet for haemodialysis patients with moderate-to-severe secondary hyperparathyroidism in China: evaluation based on the EVOLVE trial. BMJ open, 2020, 08-04, Volume: 10, Issue:8 Topics: China; Cinacalcet; Cost-Benefit Analysis; Humans; Hyperparathyroidism, Secondary; Markov Chains; Naphthalenes; Quality-Adjusted Life Years; Renal Dialysis	2020
Effect of Cinacalcet on the Redox Status of Albumin in Secondary Hyperparathyroidism Patients Receiving Hemodialysis. Biological & pharmaceutical bulletin, 2020, Volume: 43, Issue:10 Topics: Adult; Aged; Antioxidants; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Oxidation-Reduction; Parathyroid Hormone; Renal Dialysis; Serum Albumin, Human; Treatment Outcome	2020
Association Between Treatment of Secondary Hyperparathyroidism and Posttransplant Outcomes. Transplantation, 2021, 12-01, Volume: 105, Issue:12 Topics: Adult; Aged; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Medicare; Parathyroidectomy; Renal Dialysis; United States	2021
Decreasing Surgical Management of Secondary Hyperparathyroidism in the United States. The Journal of surgical research, 2021, Volume: 264 Topics: Administrative Claims, Healthcare; Calcimimetic Agents; Cinacalcet; Female; Hospital Mortality; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroidectomy; Postoperative Complications; Practice Guidelines as Topic; Practice Patterns, Physicians'; Referral and Consultation; United States	2021
Cinacalcet and gastrointestinal bleeding risk in patients receiving hemodialysis. Pharmacoepidemiology and drug safety, 2022, Volume: 31, Issue:2 Topics: Adolescent; Adult; Aged; Calcimimetic Agents; Calcium; Case-Control Studies; Cinacalcet; Gastrointestinal Hemorrhage; Humans; Hyperparathyroidism, Secondary; Medicare; Parathyroid Hormone; Renal Dialysis; United States	2022
Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis. Frontiers in public health, 2021, Volume: 9 Topics: Calcitriol; Cinacalcet; Cost-Benefit Analysis; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Quality of Life; Renal Dialysis; Renal Insufficiency, Chronic	2021
Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological study. BMJ open, 2017, 03-27, Volume: 7, Issue:3 Topics: Adult; Alkaline Phosphatase; Calcimimetic Agents; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Female; Follow-Up Studies; France; Humans; Hyperparathyroidism, Secondary; Male; Models, Biological; Parathyroid Hormone; Pharmacoepidemiology; Prospective Studies; Reference Standards; Renal Dialysis; Treatment Outcome	2017
Cinacalcet in peritoneal dialysis patients: one-center experience. Jornal brasileiro de nefrologia, 2017, Volume: 39, Issue:1 Topics: Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Peritoneal Dialysis; Retrospective Studies	2017
Intraoperative and postoperative hyperkalaemia after total parathyroidectomy following exposure to cinacalcet in sixteen patients for renal hyperparathyroidism. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2017, Volume: 42, Issue:6 Topics: Adult; Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperkalemia; Hyperparathyroidism, Secondary; Intraoperative Complications; Male; Middle Aged; Parathyroidectomy; Postoperative Complications; Retrospective Studies	2017
Impact of calcimimetics in surgery of secondary hyperparathyroidism. Endocrinologia, diabetes y nutricion, 2017, Volume: 64, Issue:1 Topics: Adult; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroidectomy; Renal Dialysis; Retrospective Studies	2017
Mortality in dialysis patients with cinacalcet use: A large observational registry study. European journal of internal medicine, 2017, Volume: 42 Topics: Adolescent; Adult; Aged; Austria; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Registries; Renal Dialysis; Retrospective Studies; Survival Analysis; Vitamin D; Young Adult	2017
Dosing of Etelcalcetide and Cinacalcet for Secondary Hyperparathyroidism. JAMA, 2017, 05-23, Volume: 317, Issue:20 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Parathyroid Hormone; Renal Dialysis	2017
Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism-Reply. JAMA, 2017, 05-23, Volume: 317, Issue:20 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone; Renal Dialysis	2017
Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital. Journal of clinical pharmacy and therapeutics, 2017, Volume: 42, Issue:5 Topics: Adolescent; Adult; Age Factors; Aged; Asian People; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Prospective Studies; Renal Insufficiency, Chronic; Republic of Korea; Young Adult	2017
Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Kidney international, 2017, Volume: 92, Issue:5 Topics: Adult; Calcimimetic Agents; Calcitriol; Cell Transdifferentiation; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Oxyphil Cells; Parathyroid Glands; Parathyroidectomy; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Uremia; Vitamin D	2017
Estimating the Effect of Preventable Treatment Discontinuation on Health Outcomes. Epidemiology (Cambridge, Mass.), 2018, Volume: 29, Issue:1 Topics: Adult; Aged; Bias; Calcimimetic Agents; Cinacalcet; Deprescriptions; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Medication Adherence; Middle Aged; Probability; Renal Dialysis	2018
The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report. BMC nephrology, 2017, Oct-18, Volume: 18, Issue:1 Topics: Adult; Calcimimetic Agents; Carcinoma; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Neoplasms; Renal Dialysis	2017
Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients. Polish archives of internal medicine, 2017, 12-22, Volume: 127, Issue:12 Topics: Adult; Aged; Calcium-Regulating Hormones and Agents; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome	2017
[Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2017, Oct-28, Volume: 42, Issue:10 Topics: Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcimimetic Agents; Calcitriol; Calcium; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Osteocalcin; Parathyroid Hormone; Phosphorus; Renal Dialysis; Treatment Outcome	2017
Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2018, Volume: 16, Issue:3 Topics: Adult; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Drug Administration Schedule; Female; Greece; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hypophosphatemia; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Phosphates; Prospective Studies; Time Factors; Treatment Outcome	2018
Successful Reversal of Furosemide-Induced Secondary Hyperparathyroidism With Cinacalcet. Pediatrics, 2017, Volume: 140, Issue:6 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Furosemide; Humans; Hyperparathyroidism, Secondary; Infant; Magnetic Resonance Imaging; Male; Parathyroid Hormone	2017
Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients. Drugs of today (Barcelona, Spain : 1998), 2017, Volume: 53, Issue:9 Topics: Animals; Cinacalcet; Fibroblast Growth Factor-23; Humans; Hyperparathyroidism, Secondary; Medication Adherence; Parathyroid Hormone; Peptides; Renal Dialysis; Renal Insufficiency, Chronic	2017
Achieve Your Goals Together. The Easy and Reasonable Way to Treat Chronic Kidney Disease-Mineral Bone Disorder. Blood purification, 2018, Volume: 45, Issue:1-3 Topics: Calcitriol; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Goals; Humans; Hyperparathyroidism, Secondary; Minerals; Renal Dialysis; Renal Insufficiency, Chronic	2018
Treatments for secondary hyperparathyroidism in hemodialysis. Polish archives of internal medicine, 2017, 12-22, Volume: 127, Issue:12 Topics: Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Renal Dialysis	2017
Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Renal failure, 2018, Volume: 40, Issue:1 Topics: Aged; Calcimimetic Agents; Calcium; Cinacalcet; Cross-Sectional Studies; Female; Gallstones; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Prevalence; Renal Dialysis; Sex Factors; Time Factors	2018
[Dystrophic Calcinosis Cutis: a rare fearsome issue of Chronic Kidney Disease]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2018, Volume: 35, Issue:1 Topics: Calcinosis; Chelation Therapy; Cinacalcet; Female; Glomerulonephritis, Membranous; Hand Deformities, Acquired; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Middle Aged; Peritoneal Dialysis; Phosphorus; Skin Diseases; Vitamin D	2018
Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. Scientific reports, 2018, 02-01, Volume: 8, Issue:1 Topics: Aged; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Sweden	2018
Cinacalcet HCl therapy in East Asian patients and rs1042636 carriers. Clinical and experimental nephrology, 2018, Volume: 22, Issue:4 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone	2018
Case report: Electron microscopic evaluation of bone from a patient treated with cinacalcet hydrochloride, maxacalcitol, and alfacalcidol for hyperparathyroid bone disease with secondary hyperparathyroidism. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, Volume: 29, Issue:5 Topics: Biopsy; Bone Density Conservation Agents; Calcitriol; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Ilium; Microscopy, Electron; Middle Aged	2018
A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic. BMC neurology, 2018, May-07, Volume: 18, Issue:1 Topics: Aged, 80 and over; Calcimimetic Agents; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Middle Aged; Parkinsonian Disorders	2018
The Calcium-Sensing Receptor Gene Polymorphism rs1801725 and Calcium-Related Phenotypes in Hemodialysis Patients. Kidney & blood pressure research, 2018, Volume: 43, Issue:3 Topics: Calcium; Cinacalcet; Coronary Artery Disease; Female; Humans; Hyperparathyroidism, Secondary; Infections; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phenotype; Polymorphism, Single Nucleotide; Receptors, Calcium-Sensing; Renal Dialysis; Vitamin D	2018
Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism. BMC nephrology, 2018, 05-15, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Calcimimetic Agents; Calcium; Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Longitudinal Studies; Male; Middle Aged; Parathyroid Hormone; Prospective Studies; Renal Dialysis; Withholding Treatment	2018
[New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2018, Volume: 35, Issue:3 Topics: Calcimimetic Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Clinical Trials as Topic; Drug Therapy, Combination; Health Services Needs and Demand; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Parathyroid Glands; Parathyroid Hormone; Peptides; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D	2018
Facing cinacalcet-induced hypocalcemia: sit back and relax? Kidney international, 2018, Volume: 93, Issue:6 Topics: Bone and Bones; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2018
Treatment Based on Cinacalcet Reduces Oxidative Stress in Hemodialysis Patients with Secondary Hyperparathyroidism. Nephron, 2018, Volume: 139, Issue:4 Topics: Adult; Advanced Oxidation Protein Products; Aged; Calcium; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Oxidative Stress; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome	2018
Outcomes in patients with renal hyperparathyroidism requiring cinacalcet pre-operatively followed by parathyroidectomy. American journal of surgery, 2019, Volume: 217, Issue:1 Topics: Adult; Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroidectomy; Preoperative Care; Propensity Score; Renal Dialysis; Retrospective Studies; Treatment Outcome	2019
Outcomes of cinacalcet withdrawal in Australian dialysis patients. Internal medicine journal, 2019, Volume: 49, Issue:1 Topics: Aged; Alkaline Phosphatase; Australia; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Renal Dialysis; Retrospective Studies; Withholding Treatment	2019
Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease. Pediatric nephrology (Berlin, Germany), 2019, Volume: 34, Issue:1 Topics: Calcimimetic Agents; Child; Child, Preschool; Cinacalcet; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Hyperparathyroidism, Secondary; Infant; Kidney Failure, Chronic; Male; Parathyroid Hormone; Retrospective Studies; Severity of Illness Index; Treatment Outcome	2019
Evocalcet in the management of secondary hyperparathyroidism in dialysis patients. Kidney international, 2018, Volume: 94, Issue:4 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Renal Dialysis	2018
Changing landscape of the treatment of hyperparathyroidism related to end-stage renal disease-can we turn the clock backward? Surgery, 2019, Volume: 165, Issue:2 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroidectomy	2019
Treatment strategy of end stage renal disease-related hyperparathyroidism before, during, and after the era of calcimimetics. Surgery, 2019, Volume: 165, Issue:1 Topics: Adult; Aged; Australia; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Insurance, Pharmaceutical Services; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Regression Analysis; Severity of Illness Index; Time-to-Treatment	2019
Response to Comments on "Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study". Clinical drug investigation, 2019, Volume: 39, Issue:1 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Japan	2019
Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. Clinical drug investigation, 2019, Volume: 39, Issue:1 Topics: Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Japan	2019
Medication Prescription Patterns for Secondary Hyperparathyroidism: More Questions than Answers. Clinical journal of the American Society of Nephrology : CJASN, 2019, 02-07, Volume: 14, Issue:2 Topics: Cinacalcet; Humans; Hyperparathyroidism, Secondary; Renal Dialysis	2019
Trimethylamine Clinical journal of the American Society of Nephrology : CJASN, 2019, 02-07, Volume: 14, Issue:2 Topics: Adult; Aged; Angina, Unstable; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Hospitalization; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Methylamines; Middle Aged; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Renal Dialysis; Stroke	2019
Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis. American journal of nephrology, 2019, Volume: 49, Issue:2 Topics: Adult; Aged; Calcimimetic Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Death, Sudden, Cardiac; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Genetic Predisposition to Disease; Glucuronidase; Heart Failure; Humans; Hyperparathyroidism, Secondary; Kaplan-Meier Estimate; Klotho Proteins; Male; Middle Aged; Multicenter Studies as Topic; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Receptor, Fibroblast Growth Factor, Type 4; Renal Dialysis	2019
Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients. Blood purification, 2019, Volume: 48, Issue:2 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Calcium; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Patient Compliance; Peptides; Prospective Studies; Renal Dialysis; Young Adult	2019
Effects of Long-Term Cinacalcet Administration on Parathyroid Gland in Hemodialysis Patients with Secondary Hyperparathyroidism. Nephron, 2019, Volume: 142, Issue:2 Topics: Aged; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Glands; Prospective Studies; Renal Dialysis	2019
Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet. British journal of clinical pharmacology, 2019, Volume: 85, Issue:6 Topics: Adolescent; Adult; Age Factors; Biomarkers; Calcimimetic Agents; Child; Child, Preschool; Cinacalcet; Computer Simulation; Drug Dosage Calculations; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Male; Models, Biological; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome	2019
Direct bone effects of calcimimetics in chronic kidney disease? Kidney international, 2019, Volume: 95, Issue:5 Topics: Animals; Bone Remodeling; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Rats; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic	2019
Activation of the calcium sensing receptor attenuates TRPV6-dependent intestinal calcium absorption. JCI insight, 2019, 04-23, Volume: 5 Topics: Animals; Calcimimetic Agents; Calcium; Calcium Channels; Cinacalcet; Disease Models, Animal; Estrenes; Female; Gene Knock-In Techniques; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hypocalcemia; Intestinal Absorption; Intestinal Mucosa; Kidney Tubules; Male; Mice; Mice, Transgenic; Oocytes; Parathyroid Hormone; Patch-Clamp Techniques; Phosphodiesterase Inhibitors; Pyrrolidinones; Receptors, Calcium-Sensing; TRPV Cation Channels; Type C Phospholipases; Xenopus	2019
Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism. Endocrine journal, 2019, Oct-28, Volume: 66, Issue:10 Topics: Adult; Calcium; Calcium-Regulating Hormones and Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Postoperative Complications; Renal Dialysis; Retrospective Studies; Survival Rate; Treatment Outcome	2019
[Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2019, Volume: 154, Issue:1 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Pyrrolidines; Randomized Controlled Trials as Topic	2019
Cinacalcet may prolong the QT interval in patients on haemodialysis with secondary hyperparathyroidism. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2013, Volume: 33, Issue:2 Topics: Cinacalcet; Electrocardiography; Humans; Hyperparathyroidism, Secondary; Middle Aged; Naphthalenes; Renal Dialysis; Time Factors	2013
Histology and immunohistochemistry of the parathyroid glands in renal secondary hyperparathyroidism refractory to vitamin D or cinacalcet therapy. European journal of endocrinology, 2013, Volume: 168, Issue:6 Topics: Adult; Aged; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Immunohistochemistry; In Vitro Techniques; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Renal Dialysis; Retrospective Studies; Vitamin D	2013
Evaluating real-world use of cinacalcet and biochemical response to therapy in US hemodialysis patients. American journal of nephrology, 2013, Volume: 37, Issue:4 Topics: Adolescent; Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Male; Middle Aged; Naphthalenes; Parathyroid Neoplasms; Phosphorus; Renal Dialysis; United States; Vitamin D; Young Adult	2013
Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients. American journal of nephrology, 2013, Volume: 37, Issue:5 Topics: Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Receptors, Calcium-Sensing; Renal Dialysis; Up-Regulation	2013
Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients. Nutrients, 2013, Apr-19, Volume: 5, Issue:4 Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Calcitriol; Calcium; Cinacalcet; Drug Therapy, Combination; Female; Guideline Adherence; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Uremia; Vitamins	2013
Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC nephrology, 2013, May-03, Volume: 14 Topics: Aged; Chemistry, Pharmaceutical; Cinacalcet; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroidectomy; Renal Dialysis; Treatment Outcome	2013
Massive soft tissue calcifications in severe hyperparathyroidism secondary to end-stage renal disease. Polskie Archiwum Medycyny Wewnetrznej, 2013, Volume: 123, Issue:4 Topics: Arthralgia; Calcinosis; Cinacalcet; Female; Hip; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Joint Diseases; Kidney Failure, Chronic; Middle Aged; Naphthalenes; Palpation; Parathyroidectomy; Radiography; Recurrence; Shoulder	2013
Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2013, Volume: 17, Issue:3 Topics: Bone Diseases, Metabolic; Calcimimetic Agents; Calcinosis; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Renal Dialysis; Treatment Outcome; Uremia	2013
Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet. Annals of transplantation, 2013, Jan-22, Volume: 18 Topics: Adult; Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hypercalciuria; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Naphthalenes; Nephrolithiasis; Tomography, X-Ray Computed	2013
Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. Endokrynologia Polska, 2013, Volume: 64, Issue:3 Topics: Adult; Aged; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome	2013
Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2013, Volume: 33, Issue:5 Topics: Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Ergocalciferols; Female; Follow-Up Studies; Goals; Guideline Adherence; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Peritoneal Dialysis; Phosphorus; Postoperative Complications; Practice Guidelines as Topic; Renal Dialysis; Retrospective Studies	2013
Bimaxillary full arch fixed dental implant supported treatment for a patient with renal failure and secondary hyperparathyroidism and osteodystrophy. The Journal of oral implantology, 2015, Volume: 41, Issue:2 Topics: Cinacalcet; Dental Implants; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Parathyroid Hormone	2015
Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology (Carlton, Vic.), 2014, Volume: 19, Issue:2 Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Retrospective Studies	2014
Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study. Nephron. Clinical practice, 2014, Volume: 126, Issue:1 Topics: Aged; Alkaline Phosphatase; Austria; Bone Density Conservation Agents; Calcimimetic Agents; Calcium; Cinacalcet; Ergocalciferols; Female; Germany; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic	2014
[Cinacalcet in the management of normocalcaemic secondary hyperparathyroidism after kidney transplantation: one-year follow-up multicentre study]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2014, Volume: 34, Issue:1 Topics: Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Postoperative Complications; Retrospective Studies; Time Factors	2014
Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses. Nephron. Clinical practice, 2013, Volume: 124, Issue:3-4 Topics: Adult; Aged; Apoptosis; Cells, Cultured; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Glands	2013
Targets for parathyroid hormone in secondary hyperparathyroidism: is a "one-size-fits-all" approach appropriate? A prospective incident cohort study. BMC nephrology, 2014, Aug-13, Volume: 15 Topics: Aged; Aged, 80 and over; Cinacalcet; Cohort Studies; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Prospective Studies	2014
The effect of cinacalcet on intraoperative findings in tertiary hyperparathyroidism patients undergoing parathyroidectomy. Surgery, 2014, Volume: 156, Issue:6 Topics: Adult; Cinacalcet; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Monitoring, Intraoperative; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Preoperative Care; Reference Values; Retrospective Studies; Severity of Illness Index; Treatment Outcome	2014
Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clinical journal of the American Society of Nephrology : CJASN, 2015, Jan-07, Volume: 10, Issue:1 Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Cinacalcet; Dietary Supplements; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation; Vitamin D	2015
Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience. Medicine, 2015, Volume: 94, Issue:2 Topics: Adolescent; Alkaline Phosphatase; Bone Density; Calcimimetic Agents; Child; Child, Preschool; Cinacalcet; Drug Monitoring; Female; Humans; Hyperparathyroidism, Secondary; Infant; Kidney; Kidney Function Tests; Male; Naphthalenes; Parathyroid Hormone; Patient Acuity; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Saudi Arabia; Treatment Outcome; Ultrasonography	2015
TREATMENT WITH CINACALCET INCREASES PLASMA ADIPONECTIN CONCENTRATION IN HEMODIALYZED PATIENTS WITH CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015, Volume: 21, Issue:7 Topics: Adiponectin; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Interleukin-6; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic	2015
Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study. BMC nephrology, 2015, Mar-31, Volume: 16 Topics: Adult; Aged; Analysis of Variance; Cinacalcet; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Prognosis; Proportional Hazards Models; Renal Dialysis; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; United States	2015
Evolving calciphylaxis--what randomized, controlled trials can contribute to the capture of rare diseases. Clinical journal of the American Society of Nephrology : CJASN, 2015, May-07, Volume: 10, Issue:5 Topics: Calcimimetic Agents; Calciphylaxis; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male	2015
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, Volume: 30, Issue:5 Topics: Cinacalcet; Clinical Trials as Topic; Europe; Humans; Hyperparathyroidism, Secondary; Meta-Analysis as Topic; Naphthalenes; Nephrology; Phosphates; Renal Insufficiency, Chronic; Societies, Medical; Sterols; Treatment Outcome; Vitamin D	2015
Diameter of parathyroid glands measured by computed tomography as a predictive indicator for response to cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney & blood pressure research, 2015, Volume: 40, Issue:3 Topics: Adult; Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Predictive Value of Tests; Renal Dialysis; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography	2015
Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation. Pharmacoepidemiology and drug safety, 2015, Volume: 24, Issue:10 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Retrospective Studies	2015
EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice. Wiener medizinische Wochenschrift (1946), 2015, Volume: 165, Issue:19-20 Topics: Adult; Aged; Austria; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Product Surveillance, Postmarketing; Renal Dialysis	2015
Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2015, Volume: 35, Issue:4 Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Cinacalcet; Drug Substitution; Drug Therapy, Combination; Ergocalciferols; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Postoperative Complications; Retrospective Studies	2015
Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2015, Volume: 35, Issue:4 Topics: Aged; Ambulatory Care; Calcimimetic Agents; Calcium; Cinacalcet; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Patient Satisfaction; Phosphorus; Prospective Studies; Renal Dialysis; Therapeutic Equivalency; Visual Analog Scale	2015
Discussion. Surgery, 2016, Volume: 159, Issue:1 Topics: Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Parathyroid Hormone	2016
Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis. Surgery, 2016, Volume: 159, Issue:1 Topics: Aged; Aged, 80 and over; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Prospective Studies; Renal Dialysis	2016
Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design. BMC nephrology, 2015, Oct-29, Volume: 16 Topics: Adult; Aged; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Income; Insurance Coverage; Kidney Failure, Chronic; Male; Medicare Part D; Middle Aged; Parathyroid Hormone; Phosphorus; Public Assistance; Renal Dialysis; Retreatment; Retrospective Studies; Serum Albumin; United States; Withholding Treatment	2015
Tolerance and efficacy of a low dose of the calcimimetic agent cinacalcet in controlling moderate to severe secondary hyperparathyroidism in hemodialysis patients. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2015, Volume: 26, Issue:6 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Parathyroid Hormone; Phosphates; Renal Dialysis	2015
Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2016, Volume: 36, Issue:2 Topics: Calcimimetic Agents; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone; Renal Dialysis; Retrospective Studies; Treatment Outcome	2016
Changes of Serum Total and Free Testosterone Concentrations in Male Chronic Hemodialysis Patients with Secondary Hyperparathyroidism in Response to Cinacalcet Treatment. Kidney & blood pressure research, 2016, Volume: 41, Issue:1 Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Testosterone	2016
The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2016, Volume: 27, Issue:1 Topics: Anemia; Bone Density; Calcimimetic Agents; Calcium; Cinacalcet; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Glands; Pilot Projects; Prospective Studies; Renal Dialysis	2016
Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons' Society of Japan. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2016, Volume: 20, Issue:1 Topics: Adult; Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Outcome and Process Assessment, Health Care; Parathyroidectomy; Postoperative Complications; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies	2016
Use of cinacalcet for the management of hyperparathyroidism in patients with different degrees of renal failure. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2016, Volume: 36, Issue:2 Topics: Adult; Aged; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis	2016
Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 03-01, Volume: 32, Issue:3 Topics: Aged; Biomarkers; Calcimimetic Agents; Calcitriol; Calcium; Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Japan; Kidney Failure, Chronic; Male; Middle Aged; Minerals; Parathyroid Hormone; Patient Care Planning; Phosphorus; Renal Dialysis; Vitamins	2017
Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. Clinical journal of the American Society of Nephrology : CJASN, 2016, 07-07, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cinacalcet; Female; Heart Failure; Hospital Mortality; Humans; Hyperparathyroidism, Secondary; Incidence; Infant; Infant, Newborn; Kidney Failure, Chronic; Kidney Transplantation; Length of Stay; Male; Middle Aged; Parathyroidectomy; Peripheral Vascular Diseases; Treatment Outcome; United States; Young Adult	2016
Parathyroid Ultrasonography in Renal Secondary Hyperparathyroidism: An Overlooked and Useful Procedure. Seminars in dialysis, 2016, Volume: 29, Issue:5 Topics: Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroid Glands; Ultrasonography	2016
Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism. Annals of surgical oncology, 2017, Volume: 24, Issue:1 Topics: Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Netherlands; Parathyroid Hormone; Parathyroidectomy; Retrospective Studies; Time Factors; Treatment Outcome; Vitamin D	2017
Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients. Drug design, development and therapy, 2016, Volume: 10 Topics: Adult; Aged; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Pharmacogenomic Testing; Polymorphism, Genetic; Young Adult	2016
[Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet]. Przeglad lekarski, 2016, Volume: 73, Issue:4 Topics: Adult; Aged; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome	2016
Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis. PloS one, 2016, Volume: 11, Issue:9 Topics: Aged; Aged, 80 and over; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Off-Label Use; Parathyroid Hormone; Phosphorus; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome	2016
Cinacalcet versus Parathyroidectomy in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2016, Sep-01, Volume: 54, Issue:3 Topics: Adolescent; Adult; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Parathyroidectomy; Postoperative Complications; Young Adult	2016
Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study. PloS one, 2016, Volume: 11, Issue:10 Topics: Aged; Anemia; Calcimimetic Agents; Calcitriol; Case-Control Studies; Cinacalcet; Diabetes Complications; Female; Follow-Up Studies; Glomerulonephritis; Hemoglobins; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Odds Ratio; Parathyroid Hormone; Prospective Studies; Receptors, Calcitriol; Renal Dialysis; Treatment Outcome	2016
The Effectiveness of Cinacalcet as an Adjunctive Therapy for Hereditary 1,25 Dihydroxyvitamin D3-Resistant Rickets. Journal of clinical research in pediatric endocrinology, 2017, Jun-01, Volume: 9, Issue:2 Topics: Calcimimetic Agents; Child, Preschool; Cinacalcet; Familial Hypophosphatemic Rickets; Female; Humans; Hyperparathyroidism, Secondary; Hypophosphatemia; Infant; Treatment Outcome	2017
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism. BMC nephrology, 2016, 11-15, Volume: 17, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Biomarkers; Bone Morphogenetic Proteins; Calcimimetic Agents; Cinacalcet; Female; Genetic Markers; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Prospective Studies; Renal Dialysis; Treatment Outcome	2016
Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney international, 2017, Volume: 91, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Caco-2 Cells; Calcimimetic Agents; Cinacalcet; Disease Models, Animal; Down-Regulation; Humans; Hyperparathyroidism, Secondary; Hyperuricemia; Intestinal Elimination; Intestinal Mucosa; Intestines; Kidney; Male; Neoplasm Proteins; Parathyroid Hormone; Rats, Sprague-Dawley; Renal Elimination; Time Factors; Uremia; Uric Acid	2017
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study. Wiener klinische Wochenschrift, 2017, Volume: 129, Issue:9-10 Topics: Adult; Aged; Aged, 80 and over; Austria; Calcimimetic Agents; Causality; Cinacalcet; Comorbidity; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Longitudinal Studies; Male; Middle Aged; Practice Patterns, Physicians'; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Switzerland; Treatment Outcome; Vitamin D	2017
Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2008, Volume: 18, Issue:4 Topics: Adult; Bone Diseases, Metabolic; Calcium; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Treatment Outcome; Weight Gain	2008
Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:11 Topics: Adult; Aged; Calcium; Cinacalcet; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Tacrolimus	2008
Cinacalcet reduces the set point of the PTH-calcium curve. Journal of the American Society of Nephrology : JASN, 2008, Volume: 19, Issue:12 Topics: Adult; Albumins; Alkaline Phosphatase; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Renal Dialysis	2008
Optimal TARGETs for cardiovascular safety and benefit in ESRD. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:10 Topics: Calcium; Cardiovascular Diseases; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Safety; Sterols; Vitamin D	2008
Calcimimetics, calcium set point and calcium balance. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:12 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2008
Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney international, 2008, Volume: 74, Issue:10 Topics: Animals; Aorta; Calcinosis; Cinacalcet; Disease Models, Animal; Hyperparathyroidism, Secondary; Myocardium; Naphthalenes; Parathyroid Hormone; Rats; Uremia	2008
[Is Cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2008, Volume: 28, Issue:5 Topics: Cinacalcet; Cost-Benefit Analysis; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Prospective Studies; Renal Dialysis; Severity of Illness Index	2008
Combination of sodium thiosulphate, cinacalcet, and paricalcitol in the treatment of calciphylaxis with hyperparathyroidism. The International journal of artificial organs, 2008, Volume: 31, Issue:8 Topics: Aged; Calciphylaxis; Chelating Agents; Cinacalcet; Drug Therapy, Combination; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Renal Dialysis; Thiosulfates; Treatment Outcome	2008
Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:2 Topics: Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Failure, Chronic; Middle Aged; Naphthalenes; Parathyroid Glands; Renal Dialysis	2009
[Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2008, Volume: 132, Issue:5 Topics: Allosteric Regulation; Animals; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Glands; Rats; Receptors, Calcium-Sensing; Renal Dialysis	2008
19th Annual Meeting of the Japanese Society for Kidney Bone Disease. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Receptors, Calcium-Sensing	2008
Clinical study of cinacalcet in Japan. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Asian People; Cinacalcet; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Approval; Humans; Hyperparathyroidism, Secondary; Japan; Longitudinal Studies; Naphthalenes; Renal Dialysis	2008
Changes in interventional treatment--from the viewpoint of percutaneous ethanol injection therapy. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Cinacalcet; Ethanol; Humans; Hyperparathyroidism, Secondary; Injections, Intralesional; Naphthalenes; Parathyroid Glands; Parathyroidectomy; Practice Guidelines as Topic; Renal Dialysis; Vitamin D	2008
Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issues. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Animals; Biomarkers; Calcium; Cinacalcet; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Treatment Outcome	2008
Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone). Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Renal Dialysis; Treatment Outcome; Vitamin D	2008
Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Calcium; Cinacalcet; Cost-Benefit Analysis; Ethanol; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Glands; Parathyroidectomy; Phosphorus; Quality of Life; Survival Rate	2008
Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Aged; Bone and Bones; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Drug Therapy, Combination; Fibrosis; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Middle Aged; Naphthalenes; Osteoblasts; Parathyroid Hormone; Renal Dialysis; Time Factors; Vitamin D	2008
Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2008, Volume: 12 Suppl 1 Topics: Calcium; Cinacalcet; Guidelines as Topic; Humans; Hyperparathyroidism, Secondary; Japan; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Societies, Medical	2008
Regression of parathyroid hyperplasia by calcimimetics--fact or illusion? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:3 Topics: Calcitriol; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Diseases; Naphthalenes	2009
Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clinical journal of the American Society of Nephrology : CJASN, 2009, Volume: 4, Issue:2 Topics: Adolescent; Adult; Biomarkers; Calcium; Centers for Medicare and Medicaid Services, U.S.; Cinacalcet; Databases as Topic; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Drug Utilization Review; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Outcome and Process Assessment, Health Care; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Practice Patterns, Physicians'; Renal Dialysis; Time Factors; Treatment Outcome; United States; Vitamin D; Young Adult	2009
Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:2 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Failure, Chronic; Naphthalenes; Phosphorus	2009
Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients. Clinical nephrology, 2009, Volume: 71, Issue:2 Topics: Adult; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Naphthalenes; Renal Dialysis	2009
Caring for chronic kidney disease patients: focus on mineral and bone disorders. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2009, Volume: 24, Issue:2 Topics: Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet Therapy; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Metabolic Diseases; Middle Aged; Naphthalenes; Parathyroid Hormone; Pharmaceutical Services; Phosphorus; Receptors, Calcium-Sensing; Renal Dialysis; Vitamin D	2009
Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:9 Topics: Adult; Aged; Bone and Bones; Calcium; Cinacalcet; Europe; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Minerals; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Vitamin D	2009
Mineral metabolism: Should cinacalcet be used in patients who are not on dialysis? Nature reviews. Nephrology, 2009, Volume: 5, Issue:6 Topics: Cinacalcet; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Hypocalcemia; Kidney Failure, Chronic; Naphthalenes; Renal Dialysis	2009
Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism. Journal of bone and mineral metabolism, 2010, Volume: 28, Issue:1 Topics: Acid Phosphatase; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Regeneration; Bone Remodeling; Bone Resorption; Calcium; Cinacalcet; Drug Administration Schedule; Female; Hormone Antagonists; Humans; Hyperparathyroidism, Secondary; Isoenzymes; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Tartrate-Resistant Acid Phosphatase; Time Factors	2010
Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder. Clinical journal of the American Society of Nephrology : CJASN, 2009, Volume: 4, Issue:9 Topics: Biomarkers; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome; Vitamin D	2009
Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodialysis international. International Symposium on Home Hemodialysis, 2010, Volume: 14, Issue:1 Topics: Cinacalcet; Cohort Studies; Drug Prescriptions; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Patient Compliance; Renal Dialysis	2010
Improvement in secondary hyperparathyroidism due to drug adherence monitoring in dialysis patients. Clinical nephrology, 2009, Volume: 72, Issue:3 Topics: Adult; Aged; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Patient Compliance; Prospective Studies; Renal Dialysis	2009
Does cinacalcet improve the prognosis of dialysis patients? Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2009, Volume: 13 Suppl 1 Topics: Calcium; Cinacalcet; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Phosphates; Prognosis; Renal Dialysis; Vitamin D; Vitamins	2009
Clinical issues regarding cinacalcet hydrochloride in Japan. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2009, Volume: 13 Suppl 1 Topics: Animals; Cinacalcet; Disease Models, Animal; Drug Costs; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Japan; Naphthalenes; Osteitis; Parathyroid Glands; Parathyroid Hormone; Randomized Controlled Trials as Topic; Receptors, Calcitriol; Vitamin D; Vitamins	2009
Postoperative hypocalcemia after parathyroidectomy for renal hyperparathyroidism in the era of cinacalcet. The American surgeon, 2009, Volume: 75, Issue:9 Topics: Adult; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Incidence; Male; Naphthalenes; Parathyroidectomy; Postoperative Complications; Retrospective Studies; Treatment Outcome	2009
Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2010, Volume: 21, Issue:1 Topics: Attitude of Health Personnel; Biomarkers; Bone Diseases, Metabolic; Calcium; Chelating Agents; Chronic Disease; Cinacalcet; Evidence-Based Medicine; Glomerular Filtration Rate; Guideline Adherence; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Practice Patterns, Physicians'; Renal Dialysis; Saudi Arabia; Surveys and Questionnaires; Treatment Outcome; Vitamin D; Vitamin D Deficiency	2010
[Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy]. Nephrologie & therapeutique, 2010, Volume: 6, Issue:2 Topics: Adult; Aged; Alkaline Phosphatase; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Calcium; Chelating Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans; Hydroxycholecalciferols; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Severity of Illness Index; Treatment Failure; Treatment Outcome; Vitamin D	2010
Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Nephron. Clinical practice, 2010, Volume: 115, Issue:3 Topics: Aged; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Organ Size; Parathyroid Glands; Prospective Studies; Renal Dialysis; Treatment Outcome; Ultrasonography	2010
Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:3 Topics: Acid Phosphatase; Adult; Aged; Bone Remodeling; Calcium; Cinacalcet; Collagen Type I; Female; Humans; Hyperparathyroidism, Secondary; Isoenzymes; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Peptides; Phosphorus; Renal Dialysis; Tartrate-Resistant Acid Phosphatase; Uremia	2011
[Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2010, Volume: 30, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Practice Guidelines as Topic; Renal Dialysis; Retrospective Studies	2010
Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis. Nutrition (Burbank, Los Angeles County, Calif.), 2010, Volume: 26, Issue:9 Topics: Aged; Anti-Inflammatory Agents; Calciphylaxis; Cinacalcet; Diphosphonates; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Middle Aged; Naphthalenes; Pamidronate; Parathyroidectomy; Renal Dialysis; Skin; Skin Diseases	2010
Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron. Clinical practice, 2011, Volume: 117, Issue:2 Topics: Cinacalcet; Cohort Studies; Comorbidity; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Illinois; Male; Middle Aged; Naphthalenes; Prevalence; Proportional Hazards Models; Renal Dialysis; Treatment Outcome	2011
Cinacalcet - clinical and laboratory effectiveness, concomitant treatment patterns and treatment cost: could we do better and how? Kidney & blood pressure research, 2010, Volume: 33, Issue:5 Topics: Adult; Aged; Calcium; Cinacalcet; Czech Republic; Drug Evaluation; Female; Follow-Up Studies; Health Care Costs; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Surveys and Questionnaires; Treatment Outcome	2010
Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:12 Topics: Aged; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Glands; Parathyroid Hormone	2010
Lead-time bias in studies of cinacalcet prescriptions. Kidney international, 2010, Volume: 78, Issue:6 Topics: Bias; Cardiovascular Diseases; Cause of Death; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Observation; Treatment Outcome	2010
Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplantation proceedings, 2010, Volume: 42, Issue:7 Topics: Adult; Bone and Bones; Cinacalcet; Glomerular Filtration Rate; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Naphthalenes; Parathyroid Hormone; Patient Selection; Postoperative Complications; Retrospective Studies	2010
"Real-World" use of cinacalcet for managing SHPT in different European countries: analysis of data from the ECHO observational study. Clinical nephrology, 2010, Volume: 74, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Cinacalcet; Europe; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Prospective Studies; Renal Dialysis; Retrospective Studies; Treatment Outcome	2010
Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. PharmacoEconomics, 2010, Volume: 28, Issue:11 Topics: Adult; Aged; Cinacalcet; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Female; Humans; Hyperparathyroidism, Secondary; Italy; Life Expectancy; Male; Markov Chains; Middle Aged; Models, Statistical; Naphthalenes; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome	2010
Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism following parathyroidectomy: results of the ECHO study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2011, Volume: 26, Issue:6 Topics: Aged; Calcium; Cinacalcet; Cohort Studies; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Recurrence; Renal Dialysis; Survival Rate; Treatment Outcome; Vitamin D	2011
Fetuin-mineral complex reflects extraosseous calcification stress in CKD. Journal of the American Society of Nephrology : JASN, 2010, Volume: 21, Issue:11 Topics: Aged; alpha-2-HS-Glycoprotein; Biomarkers; Blood Proteins; Calcinosis; Calcium; Case-Control Studies; Chronic Disease; Cinacalcet; Coronary Artery Disease; Female; Fibrinogen; Fibronectins; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Longitudinal Studies; Male; Middle Aged; Naphthalenes; Renal Dialysis; Severity of Illness Index	2010
Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation. Hemodialysis international. International Symposium on Home Hemodialysis, 2010, Volume: 14, Issue:4 Topics: Aged; Calcimimetic Agents; Cinacalcet; Dietary Supplements; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Prospective Studies; Renal Dialysis; Vitamin D	2010
Continuation of cinacalcet immediately after renal transplantation: a prospective cohort study. Clinical nephrology, 2010, Volume: 74, Issue:6 Topics: Adult; Biomarkers; Calcimimetic Agents; Calcium; Case-Control Studies; Chi-Square Distribution; Cinacalcet; Drug Administration Schedule; Female; Glomerular Filtration Rate; Graft Rejection; Graft Survival; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Netherlands; Parathyroid Hormone; Phosphates; Prospective Studies; Time Factors; Treatment Outcome	2010
Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism. Transplantation proceedings, 2010, Volume: 42, Issue:9 Topics: Absorptiometry, Photon; Adult; Arm Bones; Biomarkers; Bone Density; Calcimimetic Agents; Calcium; Case-Control Studies; Cinacalcet; Female; Hip Joint; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; National Institutes of Health (U.S.); Retrospective Studies; Spine; Time Factors; Treatment Outcome; United States	2010
An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective. Surgery, 2010, Volume: 148, Issue:6 Topics: Bone Density Conservation Agents; Cinacalcet; Cost Control; Costs and Cost Analysis; Ergocalciferols; Germany; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroidectomy	2010
Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice. Nephron. Clinical practice, 2011, Volume: 118, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Retrospective Studies; Treatment Outcome; Young Adult	2011
Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study. Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:1-2 Topics: Austria; Cinacalcet; Cohort Studies; Dialysis; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Prevalence; Risk Assessment; Risk Factors; Treatment Outcome	2011
Cinacalcet may reduce arterial stiffness in patients with chronic renal disease and secondary hyperparathyroidism - results of a small-scale, prospective, observational study. Clinical nephrology, 2011, Volume: 75, Issue:3 Topics: Adult; Aged; Alkaline Phosphatase; Aorta; Aortic Diseases; Biomarkers; Blood Pressure; Calcimimetic Agents; Calcium; Cinacalcet; Elasticity; Female; Humans; Hyperparathyroidism, Secondary; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Pulsatile Flow; Renal Dialysis; Spain; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left	2011
Cinacalcet in the treatment of persistent hyperparathyroidism after kidney transplantation. Clinical nephrology, 2011, Volume: 75, Issue:3 Topics: Adult; Aged; Analysis of Variance; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Retrospective Studies; Time Factors; Treatment Outcome	2011
[Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study]. Nephrologie & therapeutique, 2011, Volume: 7, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Anemia, Iron-Deficiency; Biomarkers; Calcium; Calcium Phosphates; Cinacalcet; Drug Resistance; Drug Therapy, Combination; Female; Hematinics; Hemoglobins; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Phosphorus; Pilot Projects; Prospective Studies; Renal Dialysis; Treatment Outcome	2011
[Morphological analysis of bone dynamics and metabolic bone disease. A case report of recurrent renal hyperparathyroidism]. Clinical calcium, 2011, Volume: 21, Issue:4 Topics: Adult; Carcinoma, Renal Cell; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Neoplasms; Male; Naphthalenes; Nephrectomy; Parathyroidectomy; Recurrence; Renal Dialysis; Time Factors; Transplantation, Autologous	2011
A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet. Clinical and experimental nephrology, 2011, Volume: 15, Issue:4 Topics: Anemia; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Diseases; Kidney Failure, Chronic; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Renal Dialysis	2011
Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. Journal of clinical pathology, 2011, Volume: 64, Issue:9 Topics: Cell Count; Cinacalcet; Drug Resistance; Female; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Organ Size; Oxyphil Cells; Parathyroid Glands; Renal Dialysis	2011
Tertiary hyperparathyroidism resistant to cinacalcet treatment. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2011, Volume: 15 Suppl 1 Topics: Adult; Chronic Disease; Cinacalcet; Creatinine; Drug Resistance; Female; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Diseases; Middle Aged; Naphthalenes; Parathyroid Glands; Parathyroidectomy; Treatment Outcome; Ultrasonography	2011
Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report. Renal failure, 2011, Volume: 33, Issue:7 Topics: Aged; Cinacalcet; Darbepoetin alfa; Drug Interactions; Erythropoietin; Female; Hematinics; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes; Renal Dialysis; Retrospective Studies	2011
[Cinacalcet impact on calcium homeostasis and bone remodeling in 13 renal transplanted patients with hyperparathyroidism and hypercalcaemia]. Nephrologie & therapeutique, 2012, Volume: 8, Issue:1 Topics: Adult; Aged; Bone Remodeling; Calcium; Cinacalcet; Female; Homeostasis; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Prospective Studies	2012
Use of ultrasound to assess the response to therapy for secondary hyperparathyroidism. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2011, Volume: 58, Issue:3 Topics: Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Middle Aged; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Renal Dialysis; Treatment Outcome; Ultrasonography, Doppler, Color	2011
Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience. Artificial organs, 2011, Volume: 35, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Calcium; Cinacalcet; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis	2011
Development and prevention of morphologic and ultrastructural changes in uremia-induced hyperplastic parathyroid gland. Ultrastructural pathology, 2011, Volume: 35, Issue:5 Topics: Animals; Calcitriol; Capillaries; Cinacalcet; Disease Models, Animal; Hyperparathyroidism, Secondary; Hyperplasia; Male; Naphthalenes; Nephrectomy; Organelles; Parathyroid Glands; Phosphorus; Phosphorus, Dietary; Rats; Rats, Sprague-Dawley; Uremia	2011
Refractory calciphylaxis. American journal of surgery, 2011, Volume: 202, Issue:3 Topics: Adult; Calciphylaxis; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Naphthalenes; Necrosis; Parathyroidectomy; Skin Ulcer; Thigh; Treatment Outcome; Uremia	2011
Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clinical nephrology, 2011, Volume: 76, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Randomized Controlled Trials as Topic; Young Adult	2011
Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism. Clinical nephrology, 2011, Volume: 76, Issue:4 Topics: Absorptiometry, Photon; Analysis of Variance; Bone Density; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Radius; Renal Dialysis; Treatment Outcome	2011
Regression of vascular calcification in a patient treated with cinacalcet: a case report. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2011, Volume: 31, Issue:5 Topics: Breast; Calcimimetic Agents; Calcitriol; Calcium Carbonate; Chelating Agents; Cinacalcet; Drug Therapy, Combination; Female; Graft Rejection; Hand; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Mammography; Middle Aged; Naphthalenes; Nephritis, Interstitial; Phosphorus; Polyamines; Renal Dialysis; Reoperation; Sevelamer; Vascular Calcification	2011
Multidisciplinary treatment. A therapeutic option to treat calciphylaxis. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2011, Volume: 31, Issue:5 Topics: Anti-Bacterial Agents; Antiphospholipid Syndrome; Calciphylaxis; Carcinoma, Renal Cell; Cardiovascular Diseases; Cinacalcet; Clostridium Infections; Clostridium perfringens; Combined Modality Therapy; Debridement; Foot Ulcer; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Postoperative Complications; Renal Replacement Therapy; Staphylococcal Infections; Thiosulfates	2011
[Questions about the ADVANCE study]. Nephrologie & therapeutique, 2012, Volume: 8, Issue:3 Topics: Calcitriol; Calcium Channel Agonists; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Multicenter Studies as Topic; Naphthalenes; Prospective Studies; Randomized Controlled Trials as Topic	2012
Association of cinacalcet adherence and costs in patients on dialysis. Journal of medical economics, 2011, Volume: 14, Issue:6 Topics: Age Factors; Cinacalcet; Comorbidity; Costs and Cost Analysis; Health Services; Humans; Hyperparathyroidism, Secondary; Insurance Claim Review; Medication Adherence; Naphthalenes; Renal Dialysis; Retrospective Studies; Socioeconomic Factors; United States	2011
Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism. Clinical and experimental nephrology, 2012, Volume: 16, Issue:2 Topics: Adolescent; Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Diseases; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Prospective Studies; Treatment Outcome; Ultrasonography; Young Adult	2012
Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:6 Topics: Animals; Calcium; Cell Proliferation; Cinacalcet; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Hyperparathyroidism, Secondary; Hyperplasia; Kidney Failure, Chronic; Male; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Uremia	2012
Surgical parathyroidectomy versus cinacalcet therapy: in the management of secondary hyperparathyroidism. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2012, Volume: 146, Issue:2 Topics: Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy	2012
A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries. Applied health economics and health policy, 2012, Mar-01, Volume: 10, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Calcimimetic Agents; Cinacalcet; Cost-Benefit Analysis; Europe; Female; Humans; Hyperparathyroidism, Secondary; Male; Markov Chains; Middle Aged; Naphthalenes; Quality-Adjusted Life Years; Young Adult	2012
Short-term use of cinacalcet in children on regular hemodialysis. Arab journal of nephrology and transplantation, 2012, Volume: 5, Issue:1 Topics: Adolescent; Calcimimetic Agents; Child; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Male; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic	2012
Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. Journal of medical economics, 2012, Volume: 15, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Cinacalcet; Cost-Benefit Analysis; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Models, Economic; Naphthalenes; Quality-Adjusted Life Years; United States; Young Adult	2012
Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report. Polskie Archiwum Medycyny Wewnetrznej, 2012, Volume: 122, Issue:4 Topics: Adipokines; Aged; Biomarkers; Calcimimetic Agents; Cinacalcet; E-Selectin; Endothelium, Vascular; Female; Humans; Hyperparathyroidism, Secondary; Leptin; Male; Middle Aged; Naphthalenes; Renal Dialysis; Treatment Outcome	2012
Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2012, Volume: 60, Issue:2 Topics: Aged; Cinacalcet; Cost-Benefit Analysis; Costs and Cost Analysis; Female; Humans; Hyperparathyroidism, Secondary; Japan; Kidney Failure, Chronic; Male; Markov Chains; Middle Aged; Monte Carlo Method; Naphthalenes; Parathyroidectomy; Quality-Adjusted Life Years; Renal Dialysis	2012
Measurement of serum soluble Klotho levels in CKD 5D patients: useful tool or dispensable biomarker? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:5 Topics: Cinacalcet; Female; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Male; Naphthalenes; Renal Dialysis	2012
Deal watch: Amgen builds secondary hyperparathyroidism [corrected] pipeline. Nature reviews. Drug discovery, 2012, Jun-01, Volume: 11, Issue:6 Topics: Cinacalcet; Drug Industry; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Receptors, Calcium-Sensing; Renal Dialysis	2012
Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. Journal of medical economics, 2012, Volume: 15, Issue:6 Topics: Aged; Aged, 80 and over; Calcitriol; Cinacalcet; Comorbidity; Cost-Benefit Analysis; Drug Therapy, Combination; Ergocalciferols; Fees, Pharmaceutical; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic	2012
Decrease of serum sphingosine-1-phosphate levels in hemodialysis patients with secondary hyperparathyroidism treated with cinacalcet. Clinical nephrology, 2012, Volume: 78, Issue:1 Topics: Aged; Biomarkers; Calcimimetic Agents; Chromatography, High Pressure Liquid; Cinacalcet; Down-Regulation; Female; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lysophospholipids; Male; Middle Aged; Naphthalenes; Renal Dialysis; Sphingosine; Treatment Outcome	2012
Cinacalcet for hemodialyzed patients with or without a high PTH level to control serum calcium and phosphorus: ECO (evaluation of cinacalcet HCl outcome) study. Clinical nephrology, 2012, Volume: 78, Issue:2 Topics: Calcium; Cinacalcet; Cohort Studies; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis	2012
Treatment of secondary hyperparathyroidism with parathyroidectomy instead of cinacalcet: time to pick the low-hanging fruit? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2012, Volume: 60, Issue:2 Topics: Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes	2012
Asymptomatic polyostotic Paget's disease associated with secondary hyperparathyroidism in a peritoneal dialysis patient. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2012, Jul-17, Volume: 32, Issue:4 Topics: Aged; Alkaline Phosphatase; Arthritis, Gouty; Asymptomatic Diseases; Bone Resorption; Calcifediol; Cinacalcet; Contraindications; Diphosphonates; Humans; Hyperparathyroidism, Secondary; Hypertension; Kidney Failure, Chronic; Male; Naphthalenes; Osteitis Deformans; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Radionuclide Imaging	2012
Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clinical journal of the American Society of Nephrology : CJASN, 2012, Volume: 7, Issue:9 Topics: Aged; Biomarkers; Bone Diseases, Metabolic; Calcimimetic Agents; Calcium; Cinacalcet; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Female; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Patterns, Physicians'; Prevalence; Prospective Studies; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Vitamin D	2012
Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clinical and experimental nephrology, 2013, Volume: 17, Issue:1 Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Calcimimetic Agents; Cinacalcet; Female; Femur Neck; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Regression Analysis; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Treatment Outcome	2013
Hyperparathyroidism in chronic kidney disease: complexities within the commonplace. Clinical medicine (London, England), 2012, Volume: 12, Issue:4 Topics: Adult; Aged; Cinacalcet; Comorbidity; Female; Humans; Hypercalcemia; Hyperparathyroidism; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Renal Insufficiency, Chronic	2012
Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism. Langenbeck's archives of surgery, 2013, Volume: 398, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Transplantation; Length of Stay; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Postoperative Complications; Preoperative Care; Retrospective Studies; Thyroidectomy	2013
[Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice - the ECHO observational study: French experience]. Nephrologie & therapeutique, 2012, Volume: 8, Issue:7 Topics: Aged; Calcimimetic Agents; Chelating Agents; Cinacalcet; Female; France; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Polyamines; Prospective Studies; Renal Dialysis; Retrospective Studies; Sevelamer; Vitamin D; Vitamins	2012
Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal. Transplantation proceedings, 2012, Volume: 44, Issue:8 Topics: Adult; Aged; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Creatinine; Drug Administration Schedule; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Time Factors; Treatment Outcome	2012
Withdrawal of cinacalcet at the time of renal transplantation is not a risk factor for allograft calcifications in the early posttransplantation period. Transplantation proceedings, 2012, Volume: 44, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Biopsy; Calcimimetic Agents; Calcinosis; Cinacalcet; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Risk Factors; Spain; Time Factors; Treatment Outcome; Young Adult	2012
Cervical tumoral calcinosis with secondary hyperparathyroidism in a chronic hemodialysis patient. Hemodialysis international. International Symposium on Home Hemodialysis, 2013, Volume: 17, Issue:3 Topics: Calcinosis; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Middle Aged; Naphthalenes; Parathyroidectomy; Renal Dialysis	2013
Trials in kidney disease--time to EVOLVE. The New England journal of medicine, 2012, Dec-27, Volume: 367, Issue:26 Topics: Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Naphthalenes; Renal Dialysis	2012
Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up. Transplantation proceedings, 2012, Volume: 44, Issue:9 Topics: Alkaline Phosphatase; Biomarkers; Calcimimetic Agents; Calcium; Cinacalcet; Creatinine; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Immunosuppressive Agents; Kidney Transplantation; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Radioimmunoassay; Retrospective Studies; Time Factors; Treatment Outcome	2012
Symmetrical craniofacial hypertrophy in patients with tertiary hyperparathyroidism and high-dose cinacalcet exposure. Hemodialysis international. International Symposium on Home Hemodialysis, 2012, Volume: 16, Issue:4 Topics: Adolescent; Adult; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypertrophy; Kidney Failure, Chronic; Male; Maxillary Sinus; Naphthalenes; Parathyroidectomy; Renal Dialysis	2012
Parathyroid hemorrhage occurring after administration of cinacalcet in a patient with secondary hyperparathyroidism. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:24 Topics: Cinacalcet; Hemorrhage; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Diseases; Parathyroid Glands; Rupture, Spontaneous	2012
[The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2012, Volume: 65, Issue:3 Topics: Administration, Oral; Adult; Aged; Calcimimetic Agents; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Failure, Chronic; Male; Middle Aged; Muscle Weakness; Naphthalenes; Parathyroid Hormone; Paresthesia; Patient Compliance; Renal Dialysis	2012
Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients. Yonsei medical journal, 2013, Mar-01, Volume: 54, Issue:2 Topics: Adult; Aged; Biomarkers, Pharmacological; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Treatment Outcome	2013
Calcimetic AMG 073 at 50 and 100 mg per day. Kidney international, 2003, Volume: 64, Issue:6 Topics: Cinacalcet; Dose-Response Relationship, Drug; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone	2003
Fooling the parathyroid gland--will there be health benefits? The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15 Topics: Calcium; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Vitamin D	2004
The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. British journal of clinical pharmacology, 2004, Volume: 57, Issue:6 Topics: Administration, Oral; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2004
Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients. The New England journal of medicine, 2004, Jul-08, Volume: 351, Issue:2 Topics: Bone Remodeling; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Predictive Value of Tests; Renal Dialysis; Treatment Outcome	2004
Cinacalcet for secondary hyperparathyroidism in hemodialysis recipients. The New England journal of medicine, 2004, Jul-08, Volume: 351, Issue:2 Topics: Calcium; Cinacalcet; Drug Administration Schedule; Heart Rate; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2004
Clinical experience with cinacalcet HCl. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004, Volume: 19 Suppl 5 Topics: Alkaline Phosphatase; Cinacalcet; Clinical Trials, Phase III as Topic; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Glands; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis	2004
Cinacalcet hydrochloride: a viewpoint by Pablo Ureña Torres. Drugs, 2005, Volume: 65, Issue:2 Topics: Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Vitamin D	2005
Cinacalcet hydrochloride: a viewpoint by Sharon M. Moe. Drugs, 2005, Volume: 65, Issue:2 Topics: Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes	2005
Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney international, 2005, Volume: 67, Issue:2 Topics: Animals; Apoptosis; Calcium; Cinacalcet; Hyperparathyroidism, Secondary; Hyperplasia; Male; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Rats; Rats, Sprague-Dawley	2005
Challenges in the therapy of secondary hyperparathyroidism. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2005, Volume: 9, Issue:1 Topics: Bone and Bones; Bone Density; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphate-Binding Proteins; Phosphates; Practice Guidelines as Topic; Renal Dialysis; Risk Factors; Vitamin D; Vitamin D Deficiency	2005
High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. Kidney international, 2005, Volume: 67, Issue:5 Topics: Calcium; Cinacalcet; Hemodialysis Solutions; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Phosphates; Renal Dialysis; Vitamin D	2005
Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:6 Topics: Adult; Bone Density; Cinacalcet; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Multicenter Studies as Topic; Naphthalenes; Parathyroid Hormone; Prospective Studies; Randomized Controlled Trials as Topic	2005
1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2005, Volume: 20, Issue:7 Topics: Animals; Aortic Diseases; Calcinosis; Calcitriol; Calcium; Calcium Channel Agonists; Chronic Disease; Cinacalcet; Disease Models, Animal; Hyperparathyroidism, Secondary; Kidney Diseases; Male; Naphthalenes; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley	2005
Calcimimetics for predialysis patients? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 47, Issue:1 Topics: Calcifediol; Chronic Disease; Cinacalcet; Dose-Response Relationship, Drug; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphates; Vitamin D; Vitamin D Deficiency	2006
Looking at calcimimetics impact on hypercalcemia of immobilization: hypotheses and a case study. Hemodialysis international. International Symposium on Home Hemodialysis, 2006, Volume: 10, Issue:1 Topics: Adult; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Immobilization; Naphthalenes; Receptors, Calcium-Sensing	2006
Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:7 Topics: Calciphylaxis; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroidectomy; Peritoneal Dialysis; Skin Ulcer; Treatment Outcome	2006
The management of secondary hyperparathyroidism. Annales d'endocrinologie, 2006, Volume: 67, Issue:2 Topics: Calcium; Cinacalcet; Diet; Humans; Hyperparathyroidism, Secondary; Lanthanum; Naphthalenes; Phosphates; Vitamin D	2006
Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clinical nephrology, 2006, Volume: 65, Issue:5 Topics: Aged; Calcium; Cinacalcet; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Receptors, Calcium-Sensing	2006
Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 47, Issue:6 Topics: Acetates; Calcitriol; Calcium; Calcium Compounds; Chronic Disease; Cinacalcet; Clinical Trials, Phase III as Topic; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic	2006
Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. Journal of bone and mineral metabolism, 2006, Volume: 24, Issue:4 Topics: Cinacalcet; Humans; Hyperparathyroidism, Primary; Hyperparathyroidism, Secondary; Immunohistochemistry; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroidectomy; Receptors, Calcitriol; Receptors, Calcium-Sensing	2006
Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism? Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:5 Topics: Adult; Aged; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Time Factors; Vitamin D	2006
Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation, 2006, Sep-15, Volume: 82, Issue:5 Topics: Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Postoperative Complications; Renal Insufficiency, Chronic; Safety	2006
Achieving targets for bone and mineral metabolism: the impact of cinacalcet HCl in clinical practice. Hemodialysis international. International Symposium on Home Hemodialysis, 2006, Volume: 10 Suppl 2 Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Retrospective Studies; Treatment Outcome	2006
Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:2 Topics: Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Middle Aged; Naphthalenes; Renal Dialysis; Time Factors	2007
Hypophosphatemia and hungry bone syndrome in a dialysis patient with secondary hyperparathyroidism treated with cinacalcet--proposal for an improved monitoring. Clinical laboratory, 2006, Volume: 52, Issue:11-12 Topics: Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Hypophosphatemia; Middle Aged; Naphthalenes; Phosphates; Renal Dialysis	2006
The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:5 Topics: Cinacalcet; Cost-Benefit Analysis; Diet Therapy; Drug Costs; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Markov Chains; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphate-Binding Proteins; Quality-Adjusted Life Years; United Kingdom; Vitamin D	2007
Cinacalcet for the treatment of calciphylaxis. Archives of dermatology, 2007, Volume: 143, Issue:2 Topics: Calciphylaxis; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Leg Ulcer; Male; Middle Aged; Naphthalenes	2007
Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation, 2007, Mar-15, Volume: 83, Issue:5 Topics: Adult; Aged; Calcium; Cinacalcet; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Phosphorus; Retrospective Studies	2007
[How to slow down parathyroid hormone (PTH) secretion without the risk of inducing an adynamic bone disease]. Nephrologie & therapeutique, 2005, Volume: 1 Suppl 4 Topics: Bone Diseases; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone	2005
Successful use of cinacalcet HCl in a patient with end-stage renal failure and refractory secondary hyperparathyroidism due to parathyromatosis. Clinical nephrology, 2007, Volume: 67, Issue:3 Topics: Aged; Calcium; Choristoma; Cinacalcet; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Naphthalenes; Parathyroid Glands; Parathyroid Hormone; Parathyroidectomy; Radionuclide Imaging; Radiopharmaceuticals; Reoperation; Retrospective Studies; Technetium Tc 99m Sestamibi; Thoracic Surgery, Video-Assisted; Thyroid Diseases; Tomography, X-Ray Computed	2007
Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Cinacalcet; Drug Administration Schedule; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Renal Dialysis	2007
Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:7 Topics: Adult; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Prospective Studies; Recurrence; Retreatment; Treatment Outcome	2007
Cinacalcet-associated cardiogenic shock in a patient with cardiomyopathy. Clinical therapeutics, 2007, Volume: 29, Issue:2 Topics: Calcium; Cardiomyopathies; Cardiotonic Agents; Cinacalcet; Drug Administration Schedule; Heart Failure; Hemofiltration; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Probability; Shock, Cardiogenic	2007
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:5 Topics: Cardiovascular Diseases; Cinacalcet; Double-Blind Method; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Randomized Controlled Trials as Topic; Renal Dialysis	2007
12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clinical nephrology, 2007, Volume: 68, Issue:1 Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Time Factors	2007
Cost-utility analysis of cinacalcet in addition to standard of care in the UK. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:11 Topics: Cinacalcet; Cost-Benefit Analysis; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; United Kingdom	2007
Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:4 Topics: Calcium; Cinacalcet; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gastrointestinal Hormones; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Radioimmunoassay; Renal Dialysis; Severity of Illness Index; Substance P; Treatment Outcome; Vasoactive Intestinal Peptide	2008
Cinacalcet, fetuin-A and interleukin-6. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:4 Topics: alpha-2-HS-Glycoprotein; Blood Proteins; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Interleukin-6; Kidney Failure, Chronic; Naphthalenes; Renal Dialysis; Treatment Outcome	2008
Cinacalcet: benefit and cost. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:4 Topics: Cinacalcet; Cost-Benefit Analysis; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2008
[Treatment of secondary hyperparathyroidism in dialysis: Report of a case-study of treatment failure]. Nephrologie & therapeutique, 2008, Volume: 4, Issue:1 Topics: Adult; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Renal Dialysis; Treatment Refusal	2008
Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. Transplantation proceedings, 2007, Volume: 39, Issue:10 Topics: Cinacalcet; Creatinine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Naphthalenes; Tacrolimus	2007
[Basic and clinical aspects of calcimimetics. Calcimimetics from the viewpoint of medical cost]. Clinical calcium, 2008, Volume: 18, Issue:1 Topics: Cinacalcet; Humans; Hyperparathyroidism, Secondary; Japan; Naphthalenes; Receptors, Calcium-Sensing	2008
[Basic and clinical aspects of calcimimetics. The clinical effect and usefulness of Cinacalcet as a calcimimetics on three CKD-5D patients undergoing hemodialysis with refractory secondary hyperparathyroidism]. Clinical calcium, 2008, Volume: 18, Issue:1 Topics: Aged; Calcium; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Receptors, Calcium-Sensing; Renal Dialysis	2008
Cinacalcet as first-line treatment for calciphylaxis. Acta dermato-venereologica, 2008, Volume: 88, Issue:1 Topics: Aged; Calciphylaxis; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Receptors, Calcium-Sensing; Skin Ulcer	2008
Cinacalcet and the prevention of secondary hyperparathyroidism in rats with aldosteronism. The American journal of the medical sciences, 2008, Volume: 335, Issue:2 Topics: Aldosterone; alpha 1-Antitrypsin; Animals; Calcium; Cinacalcet; Hydrogen Peroxide; Hyperaldosteronism; Hyperparathyroidism, Secondary; Leukocytes, Mononuclear; Male; Myocardium; Naphthalenes; Oxidative Stress; Parathyroid Hormone; Rats; Rats, Sprague-Dawley	2008
Cinacalcet is efficacious in pediatric dialysis patients. Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:10 Topics: Adolescent; Alkaline Phosphatase; Child; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes; Parathyroid Hormone; Renal Dialysis	2008
Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2008, Volume: 8, Issue:4 Topics: Area Under Curve; Calcitonin; Calcium Phosphates; Cholecalciferol; Cinacalcet; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Naphthalenes; Parathyroid Hormone	2008
Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism? Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:3 Topics: Adult; Aged; Body Mass Index; Calcitriol; Cinacalcet; Drug Therapy, Combination; Female; Humans; Hyperparathyroidism, Secondary; Hyperplasia; Logistic Models; Male; Middle Aged; Naphthalenes; Oxyphil Cells; Parathyroid Glands; Parathyroidectomy; Phosphates; Receptors, Calcitriol; Receptors, Calcium-Sensing; Renal Dialysis; Risk Assessment; Risk Factors; Sex Factors; Treatment Failure; Uremia; Vitamins	2008
Massive soft tissue calcifications and cinacalcet. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:4 Topics: Adult; Calcinosis; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Male; Naphthalenes	2008
Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatric nephrology (Berlin, Germany), 2008, Volume: 23, Issue:10 Topics: Adolescent; Adult; Calcium; Child; Child, Preschool; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Infant; Kidney Failure, Chronic; Male; Naphthalenes; Parathyroid Hormone; Phosphorus	2008